THE SCIENCE OF LEADERSHIP

Annual Report 2018
Our overhead is paid from our endowment and Damon Runyon Broadway Tickets, allowing 100% of your donation to support cancer research.

### Financial Summary

**Fiscal Year 2018**

As in previous years, the financial activities of the Damon Runyon Cancer Research Foundation were audited by RMS US LLP. Below is a snapshot of FY2018.

For our complete audited financial statements, please visit our website at [WWW.DAMONRUNYON.ORG](http://WWW.DAMONRUNYON.ORG).

<table>
<thead>
<tr>
<th></th>
<th><strong>2017</strong></th>
<th><strong>2018</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Assets</td>
<td>$142,411,870</td>
<td>$148,707,992</td>
</tr>
<tr>
<td>Total Liabilities</td>
<td>$30,256,220</td>
<td>$32,236,227</td>
</tr>
<tr>
<td>Total Net Assets</td>
<td>$112,155,650</td>
<td>$116,471,765</td>
</tr>
</tbody>
</table>

### Award Programs

- **83.5%**

### Fundraising

- **14.0%**

### General Administration

- **2.5%**

### Total Operating Expenses

**TOTAL**

- **Contributions** 56.2%
- **Damon Runyon Broadway Tickets** 3.3%
- **Donated Services** 3.7%
- **Bequests and Trusts** 8.3%
- **Misc. Income** 1.0%
- **Allocation from Investments** 27.5%

### Total Revenue

**TOTAL**

- **Contributions** 56.2%
- **Damon Runyon Broadway Tickets** 3.3%
- **Donated Services** 3.7%
- **Bequests and Trusts** 8.3%
- **Misc. Income** 1.0%
- **Allocation from Investments** 27.5%
Leadership is at the core of our mission. We do not simply fund cancer research. We identify and enable new generations of future scientific leaders capable of discovering radical new approaches to how we prevent, diagnose and cure the many forms of cancer.

We do this because it will take exceptional people to ultimately defeat a disease as pernicious and wily as cancer. We select these young scientists with great care and provide them with funding, mentorship, and support. They then go on to lead the most innovative and paradigm-shifting research—research that has saved and will continue to save lives.

At the end of this year, our current President and Chief Executive Officer, Lorraine W. Egan, is stepping down after 18 years at the helm of the Damon Runyon Cancer Research Foundation.

She will be succeeded by Yung S. Lie, PhD, our Deputy Director and Chief Scientific Officer. At this momentous time for Damon Runyon, it is fitting that the theme of this year’s annual report is leadership.

In the pages that follow, we share our thoughts on leadership and how we are paving the way for new breakthroughs against cancer by finding and fostering the scientific leaders who will make the end of all suffering from cancer a reality.
Our Next Leader

When our Fellowship Award Committee selected Yung S. Lie, PhD, as a Damon Runyon Fellow in 2000, little did they know that they were picking Damon Runyon’s future President and CEO. She will be the first scientist and alumna to lead the organization since it was founded in 1946.

Dr. Lie received her BA degree from UC Berkeley and her PhD from Stanford University. As a Damon Runyon Fellow from 2001-2004, Dr. Lie studied how cells migrate and navigate their environment at the University of California, San Francisco and The Rockefeller University. She joined Damon Runyon in 2008 and currently serves as its Deputy Director and Chief Scientific Officer. Under her leadership, Damon Runyon scientists have pioneered the fields of immunotherapy, genomic and precision medicine; its award programs have expanded to target the greatest areas of need in cancer research; and Damon Runyon’s research funding has grown by 225%, to more than $18 million annually.

Dr. Lie’s postdoctoral mentor, Mary Beth Hatten, PhD, Professor at The Rockefeller University and member of the National Academy of Sciences, calls her “a superb scientist and astute judge of scientific talent. Congratulations to Damon Runyon on an outstanding choice to lead their organization.”
In the scientific community, Damon Runyon is held in the highest esteem for its commitment to young scientists and rigor in selecting the best of the best. I am thrilled and honored to continue this important work and am confident that it will lead to new breakthroughs against cancer.

Yung S. Lie, PhD
The following are edited excerpts from an interview with Lorraine W. Egan, current President of the Damon Runyon Cancer Research Foundation, and her successor, Yung S. Lie, PhD. For video of the full interview, visit www.damonrunyon.org.

EXECUTIVE Q&A

Reflections on Leadership

Lorraine, what makes Damon Runyon a leader in cancer research?

Lorraine: The most important thing that comes to mind when I think about Damon Runyon is its commitment to excellence. We stand for excellence in the science that we fund, but also in terms of how we run our organization and steward our donors’ gifts. Our donors are incredibly generous to support us and we take that very seriously. Our Board of Directors looks for excellence in the people to lead the organization. I’m honored that they selected me years ago and now it’s incredible for me to pass the baton to somebody who is, first of all, a Damon Runyon alumna and, secondly, clearly the right person to lead Damon Runyon going forward. It’s the ultimate success that we can have a seamless transition and maintain the quality and excellence of our organization.
As a scientist and former award recipient, Yung is the ideal person to lead our organization. She completely understands our mission. She understands the science. I can’t think of a better person to take the helm of Damon Runyon.

LOURNAE W. EGAN

What makes Yung the best choice to lead Damon Runyon?

Lorraine: It's exciting for me to be able to hand off the leadership to such a perfect person. Damon Runyon is all about the science. It is more important to us than anything, that we fund the best scientists doing paradigm-shifting work. As a scientist and former award recipient, Yung is the ideal person to lead our organization. She completely understands our mission. She understands the science. I can’t think of a better person to take the helm of Damon Runyon.

As the outgoing CEO of Damon Runyon, what advice do you have for her?

Lorraine: I'm not sure Yung needs any advice because she's so incredibly talented, but what has made us a good team, and what she'll carry on, is staying focused on our mission. It's all about the science and the scientists. If we stay true to that, no matter where the science goes and what new discoveries are made, funding brilliant people is always going to be the secret to success.

Yung, what are you particularly excited about moving forward in this new role?

Yung: We are funding more research and more scientists than ever before, and there's the capacity to do more. I'm excited about the opportunity to work with our scientific leadership to identify the right places for Damon Runyon to fund more cancer research to make a greater impact.

Lorraine: The science is moving so fast and the discoveries are incredible. It's possible that during Yung's tenure as CEO tremendous breakthroughs will be made in cancer and more and more people's lives will be saved. I'll be a little jealous not to be at the helm for that.

As a female scientist yourself, can you talk about some of the challenges that female scientists have?

Yung: Science is a particularly challenging career path for everyone, but we know that for women it is especially difficult to balance a very demanding career with having a young family and trying to be successful in all aspects of their lives. At Damon Runyon, we try to support our women scientists in ways that help them get through these times that can be very difficult. We help by providing all of our scientists who have young children with a childcare allowance and also provide women with additional resources to bring their children to our retreats, for example. We can also be mentors and provide additional support and advice as they need it.

Are you ready to take the helm?

Yung: I feel very excited, honored and confident about stepping into this new role as the CEO at Damon Runyon. In part, it's because of the deep history and experience that I've had with Damon Runyon—having been a Fellow myself and then leading the scientific programs for so many years. Lorraine has been an incredible person to work with and to learn from, and so I do feel that I'm in the absolute best position to now move into this role.
The Science of Identifying Future Leaders

Twelve scientists funded by Damon Runyon have received the Nobel Prize. Seventy-four are members of the prestigious National Academy of Sciences. Countless others are behind recent progress in precision medicine and immunotherapy, and spearheading promising and diverse new fields of research.

What is behind this stellar track record in choosing future leaders? Award selection committees that are as creative, risk-taking and scientifically diverse as the candidates they evaluate.

The world-renowned scientists on Damon Runyon’s award committees hail from the nation’s most prestigious research organizations and academic institutions. They are laser-focused on selecting the most brilliant young scientists and providing the support needed to turn their high-risk ideas into breakthroughs against cancer.

For William G. Kaelin, Jr., MD, Damon Runyon Board Member and Vice Chair of Scientific Programs, a rigorous selection process is key to identifying these rising stars.

“For our junior faculty awards, finalists must pitch their proposals in person, a dynamic process that allows committee members to interact with applicants in real time. Are they fearless, willing to push outside of their comfort zone, or are they going to take the obvious path? “We like people who ask big, important, interesting questions, and they have to be courageous in the way they pursue them.”

The award selection committees also think broadly about the best science to fund. As Dr. Kaelin observes, “You can’t always predict what
the outcomes of the work are going to be. The person who’s working on breast cancer might break the back of some other cancer problem unrelated to breast cancer."

Rachel Green, PhD, Chair of the Fellowship Award Committee and also a former Damon Runyon Fellow, says, “Our role is to do our very best to help come up with a balanced set of views on the committee. That really does enable us to pick the best set of people.” Dr. Green, a biochemist, acknowledges, “The committee members’ diverse backgrounds allow them to identify the exciting ideas and approaches across many disciplines as they emerge to understand and target cancer.” And new doesn’t always mean better. “Something isn’t good just because it uses new methods and doesn’t ask hard questions,” says Dr. Green.

This explains why Damon Runyon alumni dominate the biomedical ecosystem—running top-tier research laboratories, publishing landmark studies and founding biotech companies to move their discoveries to patients.

Dr. Kaelin emphasizes that Damon Runyon plays a critical role in keeping the most promising scientists engaged in cancer research. “I can’t help but wonder how many of these people, along with their potential contributions toward improving cancer care, would be lost without the support of Damon Runyon and its generous donors.”

William G. Kaelin, Jr., MD

- Damon Runyon Board Member and Vice Chair, Scientific Programs, 2016–Present
- Chair, Physician-Scientist Training Award Committee, 2015–Present
- Member, Clinical Investigator Award Committee, 2006–2016, Chair, 2013–2016
- Dana-Farber Cancer Institute/Harvard Cancer Center

Rachel Green, PhD

- Chair, Fellowship Award Committee, 2018–present, Member 2015–2018
- Member, Innovation Award Committee, 2008–2014
- Damon Runyon Fellow, 1993–1996
- Johns Hopkins University School of Medicine
Mentorship is a critical part of enabling young scientists to reach their highest potential.

Every day, researchers pour their energy and passion into work they hope will contribute to lifesaving discoveries, but along the way they will face experimental failures and disappointment. Strong mentors not only support them through these rough times, but also foster the skills needed to have long and successful careers in research.
Damon Runyon Board Member and former Damon Runyon Fellow Elaine V. Fuchs, PhD, is exactly the kind of mentor we seek. First and foremost, her own career makes her the perfect role model. She is one of the most renowned cell biologists today, highly recognized for her breakthrough discoveries regarding the biology of the skin and the role of stem cells in communicating with immune, dermal, and other cells in their environment. She is a Professor at The Rockefeller University, a Howard Hughes Medical Institute Investigator, and has received numerous prestigious awards for her groundbreaking science.

Beyond her personal success, she has trained many of the current leaders in science, including seven Damon Runyon scientists. “Developing young researchers to be tomorrow’s leaders is critical to the future of discovery,” says Dr. Fuchs.

Julie Segre, PhD, currently at the National Human Genome Institute, completed her Damon Runyon Fellowship with Dr. Fuchs. “Elaine fostered a vibrant scientific environment, where you were challenged to be fearless. She pushed her mentees out of their comfort zones to find unconventional solutions to the problems they were investigating,” says Dr. Segre.

The scientists coming out of the Fuchs lab are not only trained in laboratory science, but also the business and infrastructure of running a lab. They learn how to advocate for themselves, have direction and purpose, network, and communicate their research. “Elaine has this exquisite ability, like an oracle, to see where the field is going and navigate in that direction. That isn’t always intuitive. Working with her, you hone that skill,” explains Dr. Segre.

Dr. Segre now mentors many others—including Damon Runyon-Dale F. Frey Breakthrough Scientist and former Fellow Shruti Naik, PhD. They met at the National Institutes of Health during Dr. Naik’s graduate studies. Dr. Naik went on to work under Dr. Fuchs for her Damon Runyon Fellowship before launching her own lab at New York University School of Medicine this year. “My mentors have been my anchors in science. Julie, along with my graduate advisor and Elaine, have been fantastic in leading by example. They are really daring scientists, who ask big questions,” says Dr. Naik.

“Ultimately, the level at which science can advance depends on investing time and effort in emerging leaders,” says Dr. Fuchs.

As a mentor, that requires answering questions, probing those failed experiments, and being open-minded to new ideas. It also means taking the time to understand the individual in the lab coat. “By doing this, you empower them to go out into the world and do great things,” adds Dr. Naik.
Successful Leadership—Our Ultimate Goal

Damon Runyon has countless examples of scientists we identified and supported as young scientists who have gone on to become leaders in research.

Jedd D. Wolchok, MD, PhD

- Damon Runyon Clinical Investigator, 2003–2008
- Chief, Melanoma & Immunotherapeutics Service at MSK
- Director, Parker Institute for Cancer Immunotherapy at MSK

Karen’s melanoma first appeared in 2011 as a bleeding mole on her back. “They surgically removed it, and we hoped that was the end of the journey.” Within a year, melanoma had returned in the scar tissue. Six months after that, a scan revealed the cancer had spread to 24 tumors in her lungs. She was devastated. “When someone gives you a diagnosis of stage four melanoma, a thousand things go through your mind. You just want to live.” Then she found Dr. Wolchok.

Damon Runyon funded Dr. Wolchok at a time when many doubted that immunotherapy, or harnessing patients’ immune systems to attack cancers, would ever work. We believed in Dr. Wolchok and his conviction that immunotherapy would ultimately be successful and enabled him to pursue this lifesaving work.

“For the first 20 years of my career, we could expect a person to survive six or seven months, even after treatment with chemotherapy. (Patient survival) has now changed to more than three years, and sometimes indefinitely,” says Dr. Wolchok.
Jedd D. Wolchok, MD, PhD, a former Damon Runyon Clinical Investigator at Memorial Sloan Kettering Cancer Center, is a case in point. He is a scientist we take great pride in having funded long before he became an international leader in immunotherapy*, which has transformed melanoma from deadly to a treatable disease for people like Karen Taphorn.

Karen’s melanoma first appeared in 2011 as a bleeding mole on her back. “They surgically removed it, and we hoped that was the end of the journey.” Within a year, melanoma had returned in the scar tissue. Six months after that, a scan revealed the cancer had spread to 24 tumors in her lungs. She was devastated. “When someone gives you a diagnosis of stage four melanoma, a thousand things go through your mind. You just want to live.” Then she found Dr. Wolchok.

Damon Runyon funded Dr. Wolchok at a time when many doubted that immunotherapy, or harnessing patients’ immune systems to attack cancers, would ever work. We believed in Dr. Wolchok and his conviction that immunotherapy would ultimately be successful and enabled him to pursue this lifesaving work. “For the first 20 years of my career, we could expect a person to survive six or seven months, even after treatment with chemotherapy. (Patient survival) has now changed to more than three years, and sometimes indefinitely,” says Dr. Wolchok.

Dr. Wolchok led the clinical trials of the first immunotherapy approved by the FDA. He enrolled Karen in a more recent clinical trial he was leading that combined two immunotherapy drugs called checkpoint inhibitors. The drugs release the natural brakes on immune cells, allowing them to recognize and attack tumors. The results were astounding. “Karen went through the entire trial. She had no significant side effects and has had a durable complete remission, which lasts until today.”

Karen maintained her quality of life during cancer treatment. “The side effects were so slight that nobody knew I was sick, period. I did not lose my hair. I did not lose weight. I did not sleep all the time. I carried on my life just as I did before they told me that I was sick.

“I remember the day that Dr. Wolchok walked in with the scans saying, ‘The tumors are gone!’ I cried, and he said, ‘Why are you crying? You should be happy.’ And he was right.”

Karen Taphorn

* This year’s Nobel Prize in Physiology or Medicine recognized immunotherapy as a breakthrough that has led to an entirely new class of lifesaving drugs. Dr. Wolchok helped bring this treatment to patients by conducting the first clinical trial of the first checkpoint inhibitor approved for cancer. Watch “Anatomy of a Breakthrough,” the story of Dr. Jedd Wolchok’s cutting-edge work in immunotherapy, at www.damonrunyon.org.
DAMON RUNYON CANCER RESEARCH FOUNDATION

Board of Directors

VICE CHAIR
Scientific Programs
William G. Kaelin, Jr., MD
Professor of Medicine
Dana-Farber Cancer Institute
and Harvard Medical School
Howard Hughes Medical
Institute Investigator
Boston, Massachusetts

VICE CHAIR
Investments and Treasurer
Leon G. Cooperman
Chairman and Chief
Executive Officer
Omega Advisors, Inc.
New York, New York

VICE CHAIR
Audit and Secretary
Sanford W. Morhouse, Esq.
Of Counsel
Schulte Roth & Zabel LLP
New York, New York

VICE CHAIR
Board Development
Michael L. Gordon
Chief Executive Officer
and Chief Investment Officer
Angelo, Gordon & Company LP
New York, New York

VICE CHAIR
Development and Marketing
David M. Beirne
General Partner
X redirection Capital
San Francisco, California

Steven J. Burakoff, MD
Dean for Cancer Innovation
Tisch Cancer Institute
Lillian and Henry M. Stratton
Professor of Cancer Medicine
Icahn School of Medicine at
Mount Sinai
New York, New York

Deborah J. Coleman
Legal Counsel
Convexity Capital Management LP
Boston, Massachusetts

Robyn Coles
President
TRATE Properties, LLC
Boston, Massachusetts

Gary E. Erlbaum
President
GreenTree Properties
Ardmore, Pennsylvania

Thomas J. Fahey, Jr., MD
Senior Vice President Emeritus
Memorial Sloan Kettering Cancer Center
New York, New York

Buck French
General Partner
X redirection Capital
San Francisco, California

Elaine V. Fuchs, PhD
Laboratory Head, Laboratory
of Mammalian Cell Biology
and Development
Rebecca C. Lancefield Professor
The Rockefeller University
Howard Hughes Medical
Institute Investigator
New York, New York

Richard B. Gaynor, MD
President of Research
and Development
Neon Therapeutics
Cambridge, Massachusetts

Todd R. Golub, MD
Chief Scientific Officer and
Director, Cancer Program
Broad Institute of MIT and Harvard
Charles A. Dana Investigator in
Human Cancer Genetics
Dana-Farber Cancer Institute
Professor of Pediatrics
Harvard Medical School
Howard Hughes Medical
Institute Investigator
Cambridge, Massachusetts

Scott Greenstein
President and Chief Content Officer
SiriusXM
New York, New York

Steve Hayden
Vice Chairman and Chief
Creative Officer (Retired)
Ogilvy & Mather Worldwide
New York, New York

Jay W. Ireland
President and Chief Executive
Officer (Retired)
GE Africa
New York, New York

Morana Jovan-Embiris, PhD
Managing Partner
F2 Capital Ventures LLP
London, United Kingdom

Steven A. Kandarian
Chairman, President and Chief
Executive Officer
MetLife, Inc.
New York, New York

DAMON RUNYON CANCER RESEARCH FOUNDATION
Noah Knauf
General Partner
Kleiner Perkins Caufield & Byers
Menlo Park, California

Gabrielle Layton, PhD
Palo Alto, California

David M. Livingston, MD
Deputy Director, Dana-Farber/ Harvard Cancer Center
Chief, Charles A. Dana Division of Human Cancer Genetics
Emil Frei Professor of Genetics and Medicine, Harvard Medical School
Boston, Massachusetts

David G. Marshall
Chairman and Chief Executive Officer
Amerimar Realty Company
Philadelphia, Pennsylvania

John H. Myers
Director, Academy Securities
Fairfield, Connecticut

Richard J. O’Reilly, MD
Chief, Pediatric Bone Marrow Transplant Service
Memorial Sloan Kettering Cancer Center
New York, New York

Andrew S. Rachleff
President and Chief Executive Officer
Wealthfront Inc.
Redwood City, California

William M. Raveis, Jr.
Chairman and Chief Executive Officer
William Raveis Real Estate
Southport, Connecticut

Michael V. Seiden, MD, PhD
President and Chief Medical Officer
The US Oncology Network
McKesson Specialty Health
The Woodlands, Texas

Karen D. Seitz
Founder and Managing Director
Fusion Partners
New York, New York

Nancy Simonian, MD
Chief Executive Officer
Syros Pharmaceuticals, Inc.
Cambridge, Massachusetts

Cynthia Sulzberger
Wellington, Florida

Peter Van Camp
Executive Chairman
Equinix, Inc.
Redwood City, California

James A. Wells, PhD
Professor, Department of Pharmaceutical Sciences
Harry Wm. and Diana V. Hind Distinguished Professor
University of California at San Francisco
San Francisco, California

Connie Lurie
Atherton, California

I. George Miller, Jr., MD
John F. Enders Professor of Pediatrics, Prof. of Epidemiology and of Molecular Biophysics and Biochemistry
Section Chief, Pediatric Infectious Diseases
Yale School of Public Health
New Haven, Connecticut

Henry C. Pitot, MD, PhD
Professor Emeritus of Oncology, Pathology and Laboratory Medicine
523 McArdle Laboratory for Cancer Research
University of Wisconsin-Madison
School of Medicine and Public Health
Madison, Wisconsin

Katharine F. Plum
Hobe Sound, Florida

Samuel C. Silverstein, MD
John C. Dalton Professor of Physiology and Cellular Biophysics
Professor of Medicine
Columbia University College of Physicians and Surgeons
New York, New York

E M E R I T U S M E M B E R S

Sidney Altman, PhD
Professor Emeritus of Molecular, Cellular and Developmental Biology and Chemistry
Senior Research Scientist of Molecular, Cellular and Developmental Biology
Yale University
New Haven, Connecticut

David Baltimore, PhD
President Emeritus
Robert Andrews Millikan Professor of Biology
California Institute of Technology
Pasadena, California

Kenneth G. Langone
Chairman and Chief Executive Officer
Invemed Associates, LLC
New York, New York

Ronald Levy, MD
Robert K. and Helen K. Summy Professor
Stanford University School of Medicine
Stanford, California

Craig B. Thompson, MD
President and CEO
Memorial Sloan Kettering Cancer Center
New York, New York

Virginia Ueberroth
Chairman
The Ueberroth Family Foundation
Corona del Mar, California

Robert C. Wright
Senior Advisor
Lee Equity Partners, LLC
New York, New York

Robert C. Young, MD
Former Chancellor
Fox Chase Cancer Center
President, RCY Medicine
Philadelphia, Pennsylvania

Lorraine W. Egan
President and Chief Executive Officer
Damon Runyon Cancer Research Foundation
Bay Area Committee

Carson Eltoukhy  
Atherton, California

Buck French  
General Partner  
Xº Capital  
San Francisco, California

Noah Knauf  
General Partner  
Kleiner Perkins Caufield & Byers  
Menlo Park, California

Gabrielle Layton, PhD  
Palo Alto, California

Brigette Lau  
Partner  
Social Capital LP  
Palo Alto, California

Connie Lurie  
Atherton, California

Carole Middleton  
Hillsborough, California

Andrew S. Rachleff  
President and Chief Executive Officer  
Wealthfront Inc.  
Redwood City, California

Gordon M. Ringold, PhD  
Chief Executive Officer  
Quadriga Biosciences  
Palo Alto, California

Karen D. Seitz  
Founder and Managing Director  
Fusion Partners  
New York, New York

Judy Swanson  
Hillsborough, California

Peter Van Camp  
Executive Chairman  
Equinix, Inc.  
Redwood City, California

James Wells, PhD  
Professor, Department of  
Pharmaceutical Sciences  
Harry Wm. and Diana V. Hind  
Distinguished Professor  
University of California at  
San Francisco  
San Francisco, California

New York Metro Area Committee

Kathy Braddock  
Managing Director  
William Raveis New York City  
New York, New York

Melissa L. Cohn  
Executive Vice President of the  
Private Client Group at  
Family First Funding  
New York, New York

Robyn Coles  
President  
TRATE Properties  
Boston, Massachusetts

Erica Evans Gioffre  
Head of Client Engagement  
Hirtle, Callaghan & Co.  
West Conshohocken, Pennsylvania

Gerald M. Marshall  
Co-Chairman and  
Chief Executive Officer  
Amerimar Enterprises, Inc.  
New York, New York

Joseph R. Osborne, MD, PhD  
Chief of Nuclear Medicine and  
Molecular Imaging Division  
Clinical Chief of Molecular Imaging  
Innovation Institute (MI3)  
New York-Presbyterian Hospital/  
Weill Cornell Medicine  
New York, New York

Karen D. Seitz  
Founder and Managing Director  
Fusion Partners  
New York, New York
In FY2018, Damon Runyon awarded nearly **$18.3 million** to 69 newly selected, exceptional scientists.

<table>
<thead>
<tr>
<th>Award Program</th>
<th>Description</th>
<th>Award Details</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Damon Runyon-Rachleff Innovation Award</strong></td>
<td>Supports the next generation of exceptionally creative thinkers with high-risk, high-reward ideas that have the potential to significantly impact our understanding of and approaches to the prevention, diagnosis or treatment of cancer.</td>
<td><strong>TWO-YEAR AWARD: $300,000</strong> with possibility of extension up to an additional $300,000</td>
</tr>
<tr>
<td><strong>Damon Runyon Clinical Investigator Award</strong></td>
<td>Supports early career physician-scientists conducting patient-oriented research. The goal of this innovative program is to increase the number of physicians capable of moving seamlessly between the laboratory and the patient’s bedside in search of breakthrough treatments.</td>
<td><strong>THREE-YEAR AWARD: $450,000</strong> plus up to $100,000 for medical school loan repayment; with possibility of extension up to an additional $300,000</td>
</tr>
<tr>
<td><strong>Damon Runyon Fellowship Award</strong></td>
<td>Supports the training of the brightest postdoctoral scientists as they embark upon their research careers. This funding enables them to be mentored by established investigators in leading research laboratories across the country.</td>
<td><strong>FOUR-YEAR AWARD: $231,000</strong></td>
</tr>
<tr>
<td><strong>Damon Runyon-Sohn Pediatric Cancer Fellowship Award</strong></td>
<td>Supports dedicated basic scientists and clinicians who conduct research with the potential to significantly impact the prevention, diagnosis or treatment of one or more pediatric cancers.                                                                ETYPE</td>
<td><strong>FOUR-YEAR AWARD: $231,000</strong></td>
</tr>
<tr>
<td><strong>Damon Runyon-Dale F. Frey Award for Breakthrough Scientists</strong></td>
<td>Supports a select few Damon Runyon Fellows who have greatly exceeded the Foundation’s highest expectations. This additional investment in these exceptional individuals catapults their research careers and their impact on cancer.</td>
<td><strong>TWO-YEAR AWARD: $100,000</strong></td>
</tr>
<tr>
<td><strong>Damon Runyon Physician-Scientist Training Award</strong></td>
<td>Supports and encourages outstanding recent medical school graduates to pursue cancer research careers by providing them with the opportunity for a protected research training experience under the mentorship of a highly qualified and gifted mentor.</td>
<td><strong>FOUR-YEAR AWARD: $460,000</strong> plus up to $100,000 for medical school loan repayment</td>
</tr>
</tbody>
</table>
The funding has enabled me to pursue a highly innovative project, which would have been difficult to do without the help from the Foundation. It has allowed me to expand the research of my lab in a new direction.

GUILLEM PRATX, PhD
Damon Runyon-Rachleff Innovator, 2015–2018
Stanford University
DAMON RUNYON-RACHLEFF
Innovation Awards

CALIFORNIA
Rushika M. Perera, PhD
Mechanisms of cellular transformation at the signal organelle level at the University of California, San Francisco

MASSACHUSETTS
Eric S. Fischer, PhD*
Novel mechanisms for small molecule induced targeted degradation of BRM family proteins at Dana-Farber Cancer Institute, Boston

Marcela V. Maus, MD, PhD
Next-generation CAR T cells for EGFRvIII-positive glioblastoma at Massachusetts General Hospital, Boston

NEW YORK
Arnold S. Han, MD, PhD*
Precision T cell receptor-based cancer therapies at Columbia University, New York

Amaia Lujambio, PhD*
Overcoming the resistance to anti-PD1 immunotherapy in hepatocellular carcinoma at the Icahn School of Medicine at Mount Sinai, New York

Benjamin L. Martin, PhD, and David Q. Matus, PhD
Cell cycle regulation of cellular behaviors associated with cancer metastasis at Stony Brook University, Stony Brook

NORTH CAROLINA
Lawrence A. David, PhD, and Anthony D. Sung, MD*
Personalized prebiotics to optimize microbiota metabolism and improve transplant outcomes at Duke University, Durham

OHIO
Wayne O. Miles, PhD*
Maximizing pro-apoptotic protein levels at The Ohio State University, Columbus

*Initial Year

DAMON RUNYON-RACHLEFF
Innovation Award Stage 2 Funding

CALIFORNIA
Scott J. Dixon, PhD*
Exploring the role of reductive stress in promoting cancer cell death at Stanford University, Stanford

Nicholas T. Ingolia, PhD
Cis-regulatory code for the translational control of gene expression at the University of California, Berkeley

Peter J. Turnbaugh, PhD*
Nadia’s Gift Foundation Innovator
The gut microbiome: an unexpected contributor to cancer drug resistance at the University of California, San Francisco

NEW YORK
Roberto Zoncu, PhD*
Identifying and disabling organelle circuits that fuel cancer cell metabolism at the University of California, Berkeley

MARYLAND
Christopher M. Jewell, PhD
Harnessing intra-lymph node controlled release to study and enhance tumor immunity at the University of Maryland, College Park

OHIO
Christin E. Burd, PhD*
Exploiting mutational specificity to target RAS-driven melanoma at The Ohio State University, Columbus

WASHINGTON
Brian H. Shirts, MD, PhD
Participatory genetics for defining genotype-phenotype associations of rare cancer variants at the University of Washington, Seattle

WISCONSIN
Philip A. Romero, PhD*
Digital circulating tumor cell detection using scalable molecular logic at the University of Wisconsin, Madison

*Initial Year
Clinical Investigator Award Committee

CHAIR
Charles L. Sawyers, MD
Chair, Human Oncology and Pathogenesis Program
The Marie-Josée and Henry R. Kravis Chair
Howard Hughes Medical Institute Investigator
Memorial Sloan Kettering Cancer Center
New York, New York

Keara V. Ballman, PhD
Chief of the Division of Biostatistics and Epidemiology
Professor, Department of Healthcare Policy and Research
Weill Cornell Medicine
New York, New York

David P. Carbone, MD, PhD
Barbara J. Bonner Chair in Lung Cancer Research
Professor, Division of Internal Medicine
Director, James Thoracic Oncology Center
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio

Nancy E. Davidson, MD
Senior Vice President, Director and Full Member
Clinical Research Division
Fred Hutchinson Cancer Research Center
Head, Department of Medicine
Division of Medical Oncology
University of Washington
Seattle, Washington

S. Gail Eckhardt, MD
Associate Dean of Cancer Programs
Director of the LIVESTRONG Cancer Institute
Chair, Department of Oncology
Dell Medical School
The University of Texas at Austin
Austin, Texas

Howard A. Fine, MD
Director of the Brain Tumor Center
New York-Presbyterian/Weill Cornell Medical Center
Associate Director for Translational Research
Sandra and Edward Meyer Cancer Center
Fei Professor of Medicine
Chief, Division of Neuro-Oncology
Department of Neurology
Weill Cornell Medicine
New York, New York

Amato J. Giaccia, PhD
Jack, Lulu and Sam Willson Professor in Cancer Biology
Director, Division of Radiation and Cancer Biology
Department of Radiation Oncology
Stanford University School of Medicine
Stanford, California

Carl H. June, MD
Richard W. Vague Professor in Immunotherapy
Department of Pathology and Laboratory Medicine
Perelman School of Medicine
Director, Center for Cellular Immunotherapies
Director, Parker Institute for Cancer Immunotherapy
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania

Andrew L. Kung, MD, PhD
Chair, Department of Pediatrics
Memorial Sloan Kettering Cancer Center
New York, New York

Drew M. Pardoll, MD, PhD
Director, Bloomberg-Kimmel Institute for Cancer Immunotherapy
Co-Director, Cancer Immunology Program
Sidney Kimmel Comprehensive Cancer Center
Abeloff Professor in Oncology
Johns Hopkins University School of Medicine
Baltimore, Maryland

Ramon Parsons, MD, PhD
Director, Tisch Cancer Institute
Icahn Scholar
Warb-Coleman Chair Cancer Research Professor and Chairman, Department of Oncological Sciences
Icahn School of Medicine at Mount Sinai
New York, New York

David R. Piwnica-Worms, MD, PhD
Chair and Professor, Department of Cancer Systems Imaging
Deputy Division Head, Research Affairs, Division of Diagnostic Imaging
The University of Texas MD Anderson Cancer Center
Houston, Texas

Stanley R. Riddell, MD
Full Member, Fred Hutchinson Cancer Research Center
Clinical Research Division
Program in Immunology
Professor of Medicine and Oncology
University of Washington School of Medicine
Seattle, Washington

Kwok-Kin Wong, MD, PhD
Anne Murnick Cogan and David H. Cogan Professor of Oncology
Department of Medicine
Director, Division of Hematology/Medical Oncology
Laura and Isaac Perlmutter Cancer Center
NYU Langone Health
New York, New York

Sandra L. Wong, MD, MS
Chair, Department of Surgery
Senior Vice President of the Surgical Service Line
Dartmouth-Hitchcock Medical Center
The Geisel School of Medicine at Dartmouth
Lebanon, New Hampshire

FOUNDING MEMBER
Richard J. O'Reilly, MD
Chief, Pediatric Bone Marrow Transplant Service
Claire L. Tow Chair in Pediatric Oncology Research
Memorial Sloan Kettering Cancer Center
New York, New York
DAMON RUNYON
Clinical Investigator Awards

CALIFORNIA

Ami S. Bhatt, MD, PhD
Applying microbiome-based therapeutics in cancer patients with Linda Boxer, MD, PhD, and Michael P. Snyder, PhD, Stanford University School of Medicine, Stanford

Collin M. Blakely, MD, PhD*
Doris Duke-Damon Runyon Clinical Investigator
Mechanisms of incomplete response and primary resistance to osimertinib in EGFR-mutant lung cancer with Trever G. Bivona, MD, PhD, University of California, San Francisco

Catherine C. Smith, MD
Defining structure, function and therapeutic impact of oncogenic FLT3 mutations with Neil P. Shah, MD, PhD, University of California, San Francisco

ILLINOIS

Jaehyuk Choi, MD, PhD
Doris Duke-Damon Runyon Clinical Investigator
Identification of genetic basis of altered T cell receptor signaling in cutaneous T cell lymphoma with Stephen D. Miller, PhD, and John D. Crispino, PhD, Northwestern University, Chicago

 MASSACHUSETTS

Geoffrey R. Oxnard, MD
Gordon Family Clinical Investigator
Noninvasive genotyping of cell-free plasma DNA (cfDNA) as a tool for guiding personalized lung cancer care with Pasi Janne, MD, PhD, Dana-Farber Cancer Institute, Boston

Mark G. Shrieve, MD, PhD
Cash transfers for cancer surgery in West Africa: their health and economic consequences with John G. Meara, MD, DMD, MBA, Massachusetts Eye and Ear Infirmary, Boston

MISSOURI

Vivek K. Arora, MD, PhD
Defining a targetable oncogenic dyad in bladder cancer with Lee Ratner, MD, PhD, Washington University in St. Louis

Gavin P. Dunn, MD, PhD
Characterizing the immunogenic landscape of glioblastoma with John DePersio, MD, PhD, and Robert Schreiber, PhD, Washington University School of Medicine in St. Louis

NEW YORK

Vinod P. Balachandran, MD
William Raveis Charitable Fund Investigator
Defining the evolutionary dynamics and antigen potential of neoantigens for human pancreatic cancer immunotherapy with Steven D. Leach, MD, and Jedd D. Wolchok, MD, PhD, Memorial Sloan Kettering Cancer Center, New York

Christopher E. Barbieri, MD, PhD
MetLife Foundation Clinical Investigator
Presurgical trials to target distinct subclasses of localized prostate cancer with Lewis C. Cantley, PhD, Weill Cornell Medicine, New York

Adrienne A. Boire, MD, PhD
William Raveis Charitable Fund Investigator
Molecular determinants of leptomeningeal metastasis: a translational approach with Joan Massagué, PhD, Memorial Sloan Kettering Cancer Center, New York

Matthew D. Hellmann, MD*
Defining intratumoral and peripheral mechanisms mediating initiation of response, durability, and resistance to PD-1 blockade to inform rational immunotherapeutic development in NSCLC with Charles M. Rudin, MD, PhD, and Jedd D. Wolchok, MD, PhD, Memorial Sloan Kettering Cancer Center, New York

Andrew M. Intliekofe, MD, PhD*
Metabolic coupling of the hypoxic niche to stemness with Ross L. Levine, MD, Memorial Sloan Kettering Cancer Center, New York

Alex Kentsis, MD, PhD
Richard A. Lunnenden Foundation Investigator
Mechanism and function of regulatory signaling in acute myeloid leukemia with Scott A. Armstrong, MD, PhD, and Ross L. Levine, MD, Memorial Sloan Kettering Cancer Center, New York

Christopher A. Klebanoff, MD*
Clinical development of next-generation T cell receptor (TCR)-based adoptive immunotheartories for the treatment of patients with common epithelial malignancies with Michel Sadelain, MD, PhD, and Larry Norton, MD, Memorial Sloan Kettering Cancer Center, New York

Piro Lito, MD, PhD
Modeling the evolution of resistance to ERK signaling inhibitors at the single cell level with Neal X. Rosen, MD, PhD, and Charles M. Rudin, MD, PhD, Memorial Sloan Kettering Cancer Center, New York

Heather L. Yeo, MD
Use of mobile applications to evaluate post surgical recovery in aging patients with GI cancer with Manish A. Shah, MD, and Deborah Estrin, PhD, MS, Weill Cornell Medicine, New York

Pennsylvania

Brian C. Capell, MD, PhD*
Defining the role of epigenetic enhancer dysfunction in epithelial carcinogenesis with Shelley L. Berger, PhD, University of Pennsylvania, Philadelphia

*Initial Year
DAMON RUNYON

Clinical Investigator Award Continuation Grants

CALIFORNIA
L. Elizabeth Budde, MD, PhD
Targeting CD123 using chimeric antigen receptor T cells for treatment of acute myeloid leukemia with Stephen J. Forman, MD, FACP, City of Hope, Duarte

MASSACHUSETTS
Priscilla K. Brastianos, MD*
Investigation of novel targeted therapeutic approaches for brain metastases with Keith T. Flaherty, MD, and Tracy T. Batchelor, MD, Massachusetts General Hospital, Boston

Eliezer M. Van Allen, MD*
Dissecting response to conventional and emerging DNA damage and repair therapies with Geoffrey I. Shapiro, MD, PhD, Dana-Farber Cancer Institute, Boston

MISSOURI
Stephen T. Oh, MD, PhD
Targeting aberrant signaling pathways in myeloproliferative neoplasms with Daniel Link, MD, Washington University School of Medicine in St. Louis

NEW YORK
Joshua Brody, MD
William Ravets Charitable Fund Investigator Flt3L-primed ‘in situ’ vaccination for low-grade lymphomas with Nina Bhardwaj, MD, PhD, and Miriam Merad, MD, PhD, Icahn School of Medicine at Mount Sinai, New York

WASHINGTON
Aude G. Chapuis, MD*
Multifaceted transgenic TCR approach to high-risk AML with Philip D. Greenberg, MD, Fred Hutchinson Cancer Research Center, Seattle

*Initial Award

DAMON RUNYON

Fellowship Award Committee

CHAIR
Rachel Green, PhD
Howard Hughes Medical Institute Investigator
Bloomberg Distinguished Professor
Professor of Molecular Biology and Genetics
Johns Hopkins University School of Medicine
Baltimore, Maryland

VICE CHAIR
Greg Barton, PhD
Class of ’36 Endowed Chair, Department of Molecular and Cell Biology
Professor of Immunology and Pathogenesis
University of California, Berkeley
Berkeley, California

Martin D. Burke, PhD, MD
Professor of Chemistry
University of Illinois at Urbana-Champaign
Urbana, Illinois

Jayanta Chaudhuri, PhD
Professor
Immunology Program
Memorial Sloan Kettering Cancer Center
New York, New York

Jennifer Gerton, PhD
Investigator
Associate Professor, Department of Biochemistry and Molecular Biology
The University of Kansas School of Medicine
Stowers Institute for Medical Research
Kansas City, Missouri

Antonio J. Giraldez, PhD
Howard Hughes Medical Institute Scholar
Fergus F. Wallace Professor and Chair, Department of Genetics
Yale University School of Medicine
New Haven, Connecticut

Lucy A. Godley, PhD
Co-Director, Center for Clinical Cancer Genetics
Professor, Department of Medicine
Section of Hematology and Oncology
Cancer Research Center
The University of Chicago Medical Center
Chicago, Illinois
### DAMON RUNYON Fellowship Award Committee (continued)

<table>
<thead>
<tr>
<th>Name</th>
<th>Title and Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Gregory, PhD</td>
<td>Professor Department of Biological Chemistry and Molecular Pharmacology</td>
</tr>
<tr>
<td></td>
<td>Department of Pediatrics Harvard Medical School</td>
</tr>
<tr>
<td></td>
<td>Harvard Stem Cell Institute The Stem Cell Program at Boston Children's Hospital</td>
</tr>
<tr>
<td></td>
<td>Boston, Massachusetts</td>
</tr>
<tr>
<td>Howard C. Hang, PhD</td>
<td>Richard E. Salomon Family Associate Professor Laboratory of Chemical Biology</td>
</tr>
<tr>
<td></td>
<td>and Microbial Pathogenesis The Rockefeller University</td>
</tr>
<tr>
<td>E. Jane Albert Hubbard, PhD</td>
<td>Professor Department of Cell Biology Skirball Institute of Biomolecular Medicine</td>
</tr>
<tr>
<td></td>
<td>New York University School of Medicine New York, New York</td>
</tr>
<tr>
<td>Susan Kaech, PhD</td>
<td>Professor and Director NOMIS Laboratories for Immunobiology and Microbial Studies</td>
</tr>
<tr>
<td></td>
<td>NOMIS Chair Salk Institute for Biological Studies La Jolla, California</td>
</tr>
<tr>
<td>Jonathan C. Kagan, PhD</td>
<td>Professor of Pediatrics Harvard Medical School Shwachman Chair in Gastroenterology</td>
</tr>
<tr>
<td></td>
<td>Boston Children's Hospital Boston, Massachusetts</td>
</tr>
<tr>
<td>Lynne E. Maquat, PhD</td>
<td>J. Lowell Orbison Endowed Chair and Professor Department of Biochemistry and Biophysics</td>
</tr>
<tr>
<td></td>
<td>School of Medicine and Dentistry Director, University of Rochester Center for RNA Biology</td>
</tr>
<tr>
<td></td>
<td>Chair, University of Rochester Graduate Women in Science University of Rochester</td>
</tr>
<tr>
<td></td>
<td>Rochester, New York</td>
</tr>
<tr>
<td>Philip A. Newmark, PhD</td>
<td>Howard Hughes Medical Institute Investigator Burnell R. Roberts Chair in Regenerative</td>
</tr>
<tr>
<td></td>
<td>Biology Morgridge Institute for Research Department of Zoology University of Wisconsin</td>
</tr>
<tr>
<td></td>
<td>Madison, Wisconsin</td>
</tr>
<tr>
<td>Joel Rothman, PhD</td>
<td>Professor and Wilcox Family Chair in Biotechnology University of California, Santa</td>
</tr>
<tr>
<td></td>
<td>Barbara Santa Barbara, California</td>
</tr>
<tr>
<td>David Ruggero, PhD</td>
<td>Professor Helen Diller Family Endowed Chair in Basic Research University of California</td>
</tr>
<tr>
<td></td>
<td>San Francisco School of Medicine Member, UCSF Comprehensive Cancer Center San Francisco</td>
</tr>
<tr>
<td></td>
<td>California</td>
</tr>
<tr>
<td>Susan R. Schwab, PhD</td>
<td>Associate Professor Department of Pathology Skirball Institute of Biomolecular Medicine</td>
</tr>
<tr>
<td></td>
<td>New York University School of Medicine New York, New York</td>
</tr>
<tr>
<td>M. Celeste Simon, PhD</td>
<td>Scientific Director and Investigator Abramson Family Cancer Research Institute</td>
</tr>
<tr>
<td></td>
<td>Associate Director-Shared Resources, Abramson Cancer Center Arthur H. Rubenstein, MBCH</td>
</tr>
<tr>
<td></td>
<td>Professor Department of Cell and Developmental Biology University of Pennsylvania</td>
</tr>
<tr>
<td></td>
<td>Perelman School of Medicine Philadelphia, Pennsylvania</td>
</tr>
<tr>
<td>Jessica Tyler, PhD</td>
<td>Professor Department of Pathology and Laboratory Medicine Weill Cornell Medicine</td>
</tr>
<tr>
<td></td>
<td>New York, New York</td>
</tr>
<tr>
<td>Matthew G. Vander Heiden, MD, PhD</td>
<td>Eisen and Chang Career Development Professor Associate Professor of Biology Associate</td>
</tr>
<tr>
<td></td>
<td>Director, Koch Institute for Integrative Cancer Research at MIT Cambridge, Massachusetts</td>
</tr>
<tr>
<td>Amy Wagers, PhD</td>
<td>Forst Family Professor Stem Cell and Regenerative Biology Harvard University, Cambridge</td>
</tr>
<tr>
<td></td>
<td>Senior Investigator Joslin Diabetes Center Harvard Medical School Boston, Massachusetts</td>
</tr>
</tbody>
</table>
DAMON RUNYON
Fellowship Awards

C A L I F O R N I A

Salk Institute

Corina E. Antal, PhD
Robert Black Fellow
Stromal reprogramming as a therapeutic approach in pancreatic cancer with Ronald M. Evans, PhD

Jeanine L. Van Nostrand, PhD
Elucidating the AMPK-dependent regulation of mTOR signaling in the metabolic checkpoint of tumorigenesis with Reuben J. Shaw, PhD

Scripps Research Institute

Marsha M. Hirschi, PhD*
Dennis and Marsha Dammerman Fellow
Molecular engineering of an optically controlled glutamate receptor with Gabriel C. Lander, PhD

Joseph D. Schonhoff, PhD
Merck Fellow
Probing the relation between sequence, aggregation and proteotoxicity in cardiac amyloidoses caused by free antibody light chains with Jeffery W. Kelly, PhD

Xiaoyu Zhang, PhD*
Discovery of chemical probes that support targeted protein degradation in human cancer with Benjamin F. Cravatt, PhD

Stanford University

Christopher J. Cambier, PhD
HHMI Fellow
In vivo characterization of mycobacterial cording with Carolyn R. Bertozzi, PhD

Kelsie A. Eichel, PhD*
Robert A. Swanson Family Fellow
Mechanisms of polarized membrane protein trafficking with Kang Shen, PhD

Ryan A. Flynn, MD, PhD
The interplay between cellular metabolism and RNA homeostasis in disease with Carolyn R. Bertozzi, PhD

Victoria Hung, PhD
Fraternal Order of Eagles Fellow
Defining the post-translational landscape of ribosomes in control of gene regulation and cell fate with Maria Barna, PhD

John C. Janetzko, PhD*
A biophysical approach to studying GRK-GPCR complexes with Brian K. Kobilka, MD

Chuan Li, PhD*
Cosmo and Bob Lurie Fellow
Quantifying epistasis between tumor suppressor genes and revealing the underlying expression profiles at the single-cell level in murine lung adenocarcinoma with Dmitri Petrov, PhD

Jianjin Shi, PhD
Layton Family Fellow
Biochemical and genetic dissection of axon degeneration with Marc Tessier-Lavigne, PhD

Shaoqing Steven Tanq, PhD
Merck Fellow
Toward small-molecule inhibitors against human immune checkpoint PD-1 with Peter S. Kim, PhD

Leeat Yankielowicz-Keren, PhD
Studying the tumor immune microenvironment in breast cancer using a novel multiplexed imaging platform with Michael R. Angelo, MD, PhD, and Edgar G. Engleman, PhD

Anupam K. Chakravarty, PhD
Investigating the phenomenon of epigenetic inheritance mediated by non-amyloid protein aggregates with Daniel F. Jarosz, PhD

Christopher P. Lapointe, PhD*
Regulatory roles of the 3’ untranslated region in human translation with Joseph Puglisi, PhD

Kathrin Leppek, PhD
Layton Family Fellow
Mechanistic characterization of 5’UTR RNA elements that confer translational specificity to shape vertebrate embryonic development with Maria Barna, PhD

Fangfei Qu, PhD*
Decoding the molecular and cellular mechanisms of the growth of brain metastases with Julien Sage, PhD

Albert G. Tsai, MD, PhD*
Diagnosis of hematologic malignancies from paucicellular aspirate material using highly multiplexed single cell analysis with Sean C. Bendall, PhD

Jing Lin Xie, PhD*
The Mark Foundation for Cancer Research Fellow
Remembering the past: epigenetic mechanisms of cancer drug resistance with Daniel F. Jarosz, PhD

University of California, Berkeley

Gina V. Caldas, PhD
Analysis of CSR- function in C. elegans embryonic cell division with Abby F. Dernburg, PhD

Allison Didychuk, PhD*
Viral mimics of host transcription factors in oncogenic herpes viruses with Britt Glaunsinger, PhD

Stephanie Gates, PhD*
HHMI Fellow
Decoding the ubiquitin receptor recognition mechanism of the α6S proteasome with Andreas Martin, PhD

Jamie Lahvic, PhD*
The Mark Foundation for Cancer Research Fellow
Uncovering cell non-autonomous mechanisms of tumor suppression with Iwar Hartharan, MMBS, PhD

Andrew C. Murley, PhD
HHMI Fellow
Cell non-autonomous communication of ER stress resistance with Andrew G. Dillin, PhD
University of California, Los Angeles

Magdalena E. Potok, PhD
The relationship between epigenetic gene silencing, nuclear architecture, and genome stability with Steven E. Jacobsen, PhD

Christina M. Termini, PhD
Proteoglycan remodeling of the bone marrow niche regulates hematopoietic stem cell regeneration with John P. Clute, MD

University of California, San Diego

Richard W. Baker, PhD
Understanding the mechanisms of SWI/SNF-mediated chromatin remodeling and its misregulation in cancer with Andres E. Leschziner, PhD

University of California, San Francisco

Vladislav Belyy, PhD
Mapping the unfolded protein response signaling network with optogenetic actuators with Peter Walter, PhD

Kyle G. Daniels, PhD
Controlling T cell signaling and fate choice using synthetic receptors with Wendell A. Lim, PhD

Qi Hu, PhD
Design of inhibitors of cancer-associated mutant GNAS with Kevan M. Shokat, PhD

Jeffrey A. Hussmann, PhD
Rebecca Ridley Kry Fellow
Genome-wide measurement of ribosome spacing on individual transcripts with Carol A. Gross, PhD

Brian J. Laidlaw, PhD
HHMI Fellow
Role of EB1s in the regulation of lymphocyte migration during viral infection and cancer with Jason G. Cyster, PhD

Kara L. McKinley, PhD
Mechanisms and functions of cellular rearrangements in epithelia with Ronald D. Vale, PhD

Lyndsay M. Murrow, PhD
Fate specification of mammary stem cells by cell self-sorting with Zev J. Gartner, PhD

Trang Nguyen, PhD
Bypassing the unresponsiveness of T cell anergy and exhaustion with Arthur Weiss, MD, PhD

Thomas M. Norman, PhD
Identifying the stochastic determinants of drug resistance with Jonathan S. Weissman, PhD

Linda T. Vo, PhD
Off-the-shelf T cells from human pluripotent stem cells with precise tumor recognition using combinatorial antigen-sensing circuits with Jeffrey A. Bluestone, PhD

Lan Wang, PhD
Conferring organelle-specificity to tail-anchored proteins with Peter Walter, PhD

Andrew L. Wolfe, PhD
The therapeutic potential and biological effects of targeting oncogenic KRAS with Frank McCormick, PhD

Jiaxi Wu, PhD
Mechanism of dendritic cell missing-self recognition and migration to activate CD4 T cell responses with Jason G. Cyster, PhD

Yichen Xu, PhD
Elucidating the role of ER as a novel RNA-binding protein and its function in regulating translation with Davide Ruggero, PhD

Dian Yang, PhD
Dissecting intratumoral heterogeneity and hierarchy at single cell resolution with Jonathan Weissman, PhD, and Trever G. Bivona, MD, PhD

Ziyang Zhang, PhD
HHMI Fellow
Controlling the activity of bispecific T cell engagers with a chemically cleavable molecular switch with Kevan M. Shokat, PhD

CONNECTICUT

Yale School of Medicine

Zhuobin Liang, PhD
Mechanistic dissection of the Fanconi anemia pathway in coordinating R-loop processing and DNA repair with Patrick Sung, DPhil, and Gary Kupfer, MD

Esen Sefik, PhD
HHMI Fellow
The effect of microbes, diet on the intestinal immune system in the context of obesity with Richard A. Flavell, PhD

Seyed Fakhreddin Torabi, PhD
Robert Black Fellow
Evolution of triplex-forming RNAs from random sequences: a search for additional MALAT1-like triplex motifs with Joan A. Steitz, PhD

ILLINOIS

The University of Chicago

John D. Leonard, PhD
Robert Black Fellow
Self-antigen recognition by regulatory T cells with Erin J. Adams, PhD, and Peter A. Savage, PhD

Sigrid Nachtergaele, PhD
The dynamic Ni-methyladenosine methylome in eukaryotic mRNA with Chuan He, PhD

University of Illinois

Daniel J. Blair, PhD
Illini 4000 Fellow
An automated small molecule synthesizer for the discovery of new anti-cancer agents with Martin D. Burke, MD, PhD

Sarah Z. Tasker, PhD
HHMI Fellow
Synthesis and evaluation of a collection of complex molecules biased for penetration of the blood-brain barrier with Paul J. Hergenrother, PhD
MARYLAND

Johns Hopkins University School of Medicine

Xintong Dong, PhD
HHMI Fellow
Investigating ligand-receptor interactions between defensins and mrgprs in cutaneous inflammation and wound healing with Xinzhong Dong, PhD

Daniel H. Goldman, PhD
Merck Fellow
Elucidating the role of the exon junction complex in regulating translation of spliced mRNA with Rachel Green, PhD

Vu Quang Nguyen, PhD
Role of chromatin organization in dynamics of transcription initiation with Carl Wu, PhD

Evan J. Worden, PhD
The mechanistic basis of crosstalk between histone H4B ubiquitylation and H3K79 methylation with Cynthia Wolberger, PhD

Boris Zinshteyn, PhD
HHMI Fellow
Mechanisms of splicing-independent nonsense-mediated mRNA decay with Rachel Green, PhD

National Institutes of Health

Danfeng Cai, PhD
Protein crowding and protein folding landscapes as predictors of healthy and diseased cell states with Jennifer Lippincott-Schwartz, PhD

Warakorn Kulalert, PhD
Characterization of the microbiota-mediated cutaneous neuroimmune interface and its impacts on tumorigenesis and cancer therapy with Yasmine Belkaid, PhD

MASSACHUSETTS

Boston Children’s Hospital

Megan L. Insco, MD, PhD
William Rawins Charitable Fund Fellow
Investigating transcriptional cyclin dependent kinases as novel melanoma drug targets with Leonard I. Zon, MD

Yuxiang Zhang, MD, PhD
HHMI Fellow
Mechanisms that promote DNA double strand break clusters in brain and liver with Frederick W. Alt, PhD

B Brigham and Women’s Hospital

Emma V. Watson, PhD
Suzanne and Bob Wright Fellow
Metabolic stress response: Exploring transcript-level regulation of metabolic feedback with Stephen J. Elledge, PhD

Broad Institute

Matthew Bakalar, PhD
Predicting the interactions of T cell receptors with peptide-MHC complexes with Nir Hacohen, PhD

Dana-Farber Cancer Institute

Phillip A. Dumesic, MD, PhD
Identification of muscle-secreted factors responsible for local and systemic effects of exercise with Bruce M. Spiegelman, PhD

Whitney L. Johnson, PhD
Using organoid cancer models to identify genome catastrophe mechanisms with Matthew L. Meyerson, MD, PhD

Eric S. Wang, PhD
Robert Black Fellow
Enhancing anti-tumor immunity via pharmacological inhibition of kinases with Nathanael Gray, PhD

Jeffrey T. Chan School of Public Health

Jeeyun Chung, PhD
Unraveling the cellular mechanism of lipid droplet biogenesis with Tobias C. Walthier, PhD, and Robert V. Farese Jr., PhD

Harvard Medical School

Justin A. Bosch, PhD
Characterizing novel molecules and mechanisms that mediate cell-cell communication with Norbert Perrimon, PhD

Anne E. Dodson, PhD
Transgenerational inheritance of structure-based infections with Scott G. Kennedy, PhD

Ivana Gasic, PhD
Merck Fellow
Molecular elucidation of the interphase microtubule integrity response (MIR) with Timothy Mitchison, PhD

Lucy Liu, PhD
In vivo characterization of muscle autophagy in health and disease with Norbert Perrimon, PhD

Nagarajan Nandagopal, PhD
Philip O’Bryan Montgomery, Jr., MD, Fellow
Signal integration by bHLH circuits to enable cell fate decisions with Galit Lahav, PhD, and Sean Megason, PhD

Sarah J. Pfau, PhD
Investigating the molecular determinants of blood-brain barrier heterogeneity with Chenghua Gu, PhD

Deepshika Ramanan, PhD
National Mah Jongg League Fellow
Identifying functions of regulatory T cell subsets in intestinal inflammation and colorectal cancer with Christophe Benoist, MD, PhD

Justin L. Sparks, PhD
Replicative helicase bypass of bulky DNA adducts with Johannes C. Walter, PhD

Benjamin M. Stinson, PhD
Mechanism of DNA processing during non-homologous end joining with Joseph L. Loparo, PhD
Damon Runyon Fellows are incredibly enthusiastic. They are the brightest minds out there, the leaders of the scientific community. They are essentially the key to going forward in science.

**Aaron F. Straight, PhD**
Damon Runyon Fellowship Award Committee Member, 2018–Present
Damon Runyon Fellow, 1998–2001
Stanford University School of Medicine

---

Chuchu Zhang, PhD*
Molecular dissection of area postrema and its role in nausea with Stephen Liberles, PhD
Harvard University

Philip B. Abitua, PhD
Developmental mechanisms of killifish cell dispersion and aggregation with Alexander F. Schier, PhD

Brian J. Beliveau, PhD
**HHMI Fellow**
Decoding Polycomb-mediated gene regulation in single cells with single-molecule super resolution imaging and synthetic biology with Peng Yin, PhD

Monica E. McCallum, PhD
Understanding alanosine biosynthesis to discover new cancer chemotherapeutics with Emily P. Balskus, PhD

Christopher Wilson, PhD*
**Marion Abbe Fellow**
Development of a programmable writer and eraser of m6A RNA methylation with David R. Liu, PhD

Massachusetts General Hospital

Kai Mao, PhD
Mechanisms of xenobiotic surveillance and regulation with Gary B. Ruvkun, PhD

Iva Tchasovnikarova, PhD
Deciphering the role of chromatin remodeling in epigenetic repression by the HUSH complex with Robert E. Kingston, PhD

Kurt J. Warnhoff, PhD
Molybdenum cofactor biosynthetic enzymes modulate miRNA biology and development with Gary B. Ruvkun, PhD

**Massachusetts Institute of Technology**

Alexander M. Jaeger, PhD
**HHMI Fellow**
Targeting protein folding mechanisms to stimulate anti-tumor immune responses with Tyler E. Jacks, PhD

Lindsay M. LaFave, PhD
Investigating epigenetic mechanisms of transformation in SWI/SNF-mutant non-small cell lung cancer with Tyler E. Jacks, PhD

Allison N. Lau, PhD
**Robert Black Fellow**
Understanding metabolic heterogeneity in pancreatic cancer with Matthew G. Vander Heiden, MD, PhD

Evan C. Lien, PhD
Impact of diet on tumor metabolism and progression with Matthew G. Vander Heiden, MD, PhD

Jose M. Ordovas-Montanes, PhD
**HHMI Fellow**
Single-cell genomic approaches for tracing the contribution of inflammation to human colon cancer with Alex K. Shalek, PhD

Peter M. Westcott, PhD
Exploiting endogenous mutational processes in cancer to enhance response to immunotherapy with Tyler E. Jacks, PhD

**Whitehead Institute for Biomedical Research**

Laura V. Blanton, PhD
**Lallage Feazel Wall Fellow**
The impact of sex chromosome constitution on immune cell gene expression and function with David C. Page, MD

Nora Kory, PhD
**HHMI Fellow**
Identifying new components of mitochondrial one-carbon metabolism with David M. Sabatini, MD, PhD

Daniel H. Lin, PhD*
**HHMI Fellow**
Global influence of mRNA conformation on eukaryotic translational regulation with David P. Bartel, PhD

Benjamin R. Sabari, PhD
Investigating the role of aberrant genome structuring in T-ALL with Richard A. Young, PhD
The Damon Runyon Fellowship was liberating and enabling for my science, as it provided me with resources to freely test different ideas.

Sungwook Woo, PhD
Damon Runyon Fellow, 2014-2018
Harvard University
Weill Cornell Medicine

Eric E. Gardner, PharmD, PhD*  
Kenneth G. and Elaine A. Langone Fellow  
Interrogating lung adenocarcinoma transformation to small cell lung cancer at single cell resolution with Harold E. Varmus, MD

Oregon Health and Science University

Yunsik Kang, PhD*  
Molecular mechanisms regulating phagocytosis of neurons with Marc R. Freeman, PhD

University of Pennsylvania

Geoffrey P. Dann, PhD*  
Merck Fellow  
Proteomics to bridge protein arginylation, chromatin, and cancer with Benjamin A. Garcia, PhD

University of Utah

Alesia N. McKeown, PhD  
HHMI Fellow  
Novel roles for retrogenes in host immunity with Nels C. Elde, PhD, and Cedric Feschotte, PhD

University of Texas Southwestern Medical Center

Lindsay B. Case, PhD  
Robert Black Fellow  
Regulation of integrin clustering on supported lipid bilayers with Michael Rosen, PhD

Elise C. Jeffery, PhD  
Characterizing a new hematopoietic stem cell niche factor with Sean J. Morrison, PhD

UTAH

University of Utah  
School of Medicine

Ying Qi Shirleen Soh, PhD  
Mapping paths and mechanisms of virus-host adaptation with Jesse D. Bloom, PhD

Yi Yin, PhD  
Global analysis of DNA break repair by single-cell sequencing with Jay A. Shendure, MD, PhD

University of California, San Francisco

Brittany Adamson, PhD  
Damon Runyon Fellow, 2014–2017

Damon Runyon selects and supports some of the most driven research in the scientific community, but inspiration alone cannot drive progress. As with all human endeavors, practical support is essential.

Brittany Adamson, PhD  
Damon Runyon Fellow, 2014–2017  
University of California, San Francisco
The Damon Runyon-Sohn award was a vital resource for me as an early career scientist with the goal of making an impact in the treatment of pediatric cancer. I was afforded time to explore the biology of these malignancies and make discoveries that will benefit the lives of patients.

MARK W. ZIMMERMAN, PhD
Damon Runyon-Sohn Pediatric Fellow, 2014–2018
Damon Runyon-Jake Wetchler Awardee, 2016
Dana-Farber Cancer Institute
DAMON RUNYON-SOHN
Pediatric Cancer Fellowship Awards

CALIFORNIA

Özlem Aksoy, PhD
Understanding the role of translational control in humanized mouse models for medulloblastoma with Davide Ruggero, PhD, University of California, San Francisco

Zhipeng Lu, PhD
Layton Family Fellow of the Damon Runyan-Sohn Pediatric Cancer Fellowship Award
Elucidating the role of dynamic RNA structures in cancer with Howard Y. Chang, MD, PhD, Stanford University School of Medicine, Stanford

Kathryn R. Taylor, PhD
The effect of neuronal activity on pediatric glioma invasion with Michelle L. Monje, MD, PhD, Stanford University School of Medicine, Stanford

MARYLAND

Stacy L. Cooper, MD§
The Cebpa +37kb enhancer is a critical target of transformation in acute myeloid leukemia with Alan D. Friedman, MD, Johns Hopkins University, Baltimore

Michael A. Koldobskiy, MD, PhD§
DNA methylation stochasticity in pediatric pre-B cell acute lymphoblastic leukemia with Andrew P. Feinberg, MD, Johns Hopkins University, Baltimore

Cara A. Rabik, MD, PhD§
Determination of the role of WT1 in hematopoiesis and leukemogenesis with Patrick A. Brown, MD, Johns Hopkins University, Baltimore

MASSACHUSETTS

Adam D. Durbin, MD*
Interrogation of neuroblastoma dependencies and non-coding RNAs on the core-regulatory circuitry for therapeutic inhibition with A. Thomas Look, MD, Dana-Farber Cancer Institute, Boston

Amanda Balboni Iniguez, PhD
Targeting the EWS-FLI oncoprotein in Ewing sarcoma with CDK12/13 inhibitors with Kimberly Stegmaier, MD, Dana-Farber Cancer Institute, Boston

Sarah N. Olsen, PhD*
Targeted degradation of the MLL-AF9 fusion oncoprotein in acute myeloid leukemia with Scott A. Armstrong, MD, PhD, Dana-Farber Cancer Institute, Boston

MAXIMUM

Adam D. Durbin, MD*
Interrogation of neuroblastoma dependencies and non-coding RNAs on the core-regulatory circuitry for therapeutic inhibition with A. Thomas Look, MD, Dana-Farber Cancer Institute, Boston

Srinjoy Chakraborti, PhD*
Mining pHLA and T cell receptor (TCR) specificities by phage display for de novo TCR engineering and personalized cancer therapy with Jonathan R. Lai, PhD, Albert Einstein College of Medicine, Bronx

Marissa Rashkovan, PhD
Targeting metabolic vulnerabilities in ETP-ALL with Adolfo A. Ferrando, MD, PhD, Columbia University Medical Center, New York

Yadira M. Soto-Feliciano, PhD
Dissecting the role of Merin in acute leukemia with C. David Allis, PhD, The Rockefeller University, New York

WASHINGTON

Jay F. Sarthy, MD, PhD§
Characterization of the epigenomic landscape of diffuse midline gliomas with Steven Henikoff, PhD, Fred Hutchinson Cancer Research Center, Seattle

NEW YORK

Robert L. Bowman, PhD
Interrogating the subclonal architecture and functional contributions of mutation order in FLT3-ITD mutant AML with Ross L. Levine, MD, Memorial Sloan Kettering Cancer Center, New York

Srinjoy Chakraborti, PhD*
Mining pHLA and T cell receptor (TCR) specificities by phage display for de novo TCR engineering and personalized cancer therapy with Jonathan R. Lai, PhD, Albert Einstein College of Medicine, Bronx

Marissa Rashkovan, PhD
Targeting metabolic vulnerabilities in ETP-ALL with Adolfo A. Ferrando, MD, PhD, Columbia University Medical Center, New York

Yadira M. Soto-Feliciano, PhD
Dissecting the role of Merin in acute leukemia with C. David Allis, PhD, The Rockefeller University, New York

WASHINGTON

Jay F. Sarthy, MD, PhD§
Characterization of the epigenomic landscape of diffuse midline gliomas with Steven Henikoff, PhD, Fred Hutchinson Cancer Research Center, Seattle
DAMON RUNYON-DALE F. FREY AWARD
for Breakthrough Scientists

Ryan D. Baldridge, PhD*
Investigating the mechanism of retro-translocation by ERAD at the University of Michigan, Ann Arbor, Michigan

Liron Bar-Peled, PhD*
Identification of cysteine liabilities in NRP2-driven cancers at Massachusetts General Hospital, Boston, Massachusetts

Chao Lu, PhD*
Giannandrea Family Breakthrough Scientist
Chromatin dysregulation as driver of oncogenesis at Columbia University, New York, New York

Matthew P. Miller, PhD*
Deciphering tension-dependent stabilization of kinetochore-microtubule interactions at the University of Utah, Salt Lake City, Utah

Shruti Naik, PhD*
Marilyn and Scott Urdang Breakthrough Scientist
Immune-epidermal stem cell crosstalk in skin inflammation at New York University School of Medicine, New York, New York

*Initial Year

DAMON RUNYON
Physician-Scientist Training Award Committee

CHAIR
William G. Kaelin, Jr., MD
Professor of Medicine
Dana-Farber Cancer Institute and Harvard Medical School
Howard Hughes Medical Institute Investigator
Boston, Massachusetts

Lucy A. Godley, MD, PhD
Co-Director, Center for Clinical Cancer Genetics
Professor, Department of Medicine
Section of Hematology and Oncology
Cancer Research Center
The University of Chicago Medicine Chicago, Illinois

Peter S. Nelson, MD
Member, Division of Human Biology
Endowed Chair for Prostate Cancer Research
Fred Hutchinson Cancer Research Center
Professor, Division of Medical Oncology
Adjunct Professor, Genomic Sciences and Pathology
University of Washington School of Medicine
Seattle, Washington

Kornelia Polyak, MD, PhD
Professor of Medicine
Department of Medical Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Jeremy N. Rich, MD
Professor of Medicine
Director, Neuro-Oncology
Director, Brain Tumor Institute
University of California, San Diego
La Jolla, California

Cassian Yee, MD
Professor, Department of Melanoma Medical Oncology
Professor, Department of Immunology
Division of Cancer Medicine
Director, Solid Tumor Cell Therapy Center for Cancer Immunology Research
The University of Texas MD Anderson Cancer Center
Houston, Texas
Pavan Bachireddy, MD  
Coevolution of tumor and T cell heterogeneity following immunotherapy with Catherine J. Wu, MD, Dana-Farber Cancer Institute, Boston, Massachusetts

Giada Bianchi, MD, PhD  
Damon Runyon-Celgene Physician-Scientist  
Molecular mechanisms of ROBO1 in multiple myeloma pathogenesis with Kenneth C. Anderson, MD, Dana-Farber Cancer Institute, Boston, Massachusetts

Kristopher R. Bosse, MD  
GPC2 as an oncogene and immunotherapeutic target in high-risk neuroblastoma with John M. Maris, MD, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania

Julia C. Carnevale, MD  
Developing new therapeutic approaches for pancreatic cancer with homologous recombination repair defects with Alan Ashworth, PhD, University of California, San Francisco, California

Jennifer L. Caswell-Jin, MD  
Breast cancer evolution and resistance in response to HER2-targeted therapy with Christina N. Curtis, PhD, and Allison W. Kurian, MD, MSc, Stanford University, Stanford, California

Nicholas C. DeVito, MD*  
Investigating the role of EMT-mediated dendritic cell tolerization in checkpoint inhibitor resistance with Brent A. Hanks, MD, PhD, Duke University, Durham, North Carolina

Michael W. Drazer, MD  
Defining leukemogenic mechanisms in hereditary hematologic malignancies with Lucy A. Godley, MD, PhD, The University of Chicago Medicine, Chicago, Illinois

John R. Ferrarone, MD*  
Lee Cooperman Physician-Scientist  
Seeking and evaluating novel therapeutic targets in human lung adenocarcinomas with loss-of-function mutations in LKB1 with Harold E. Varmus, MD, Weill Cornell Medicine, New York, New York

Christopher J. Gibson, MD  
Elucidating the connection between clonal hematopoiesis and lymphoma in humans with Benjamin L. Ebert, MD, PhD, Dana-Farber Cancer Institute, Boston, Massachusetts

Lillian M. Guenther, MD*  
Investigation of CITED2 as a novel dependency in Ewing sarcoma with Kimberly Stegmaier, MD, Dana-Farber Cancer Institute, Boston, Massachusetts

Carolyn C. Jackson, MD, MPH  
Genetic dissection of pediatric classic Kaposi sarcoma with Jean-Laurent Casanova, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, New York

David M. Kurtz, MD, PhD  
Response prediction and personalized therapy from mathematical modeling of circulating tumor DNA in non-Hodgkin lymphoma with Arash Ash Alizadeh, MD, PhD, Stanford University School of Medicine, Stanford, California

Loretta S. Li, MD  
Mechanisms of disease and resistance in CRLF2-rearranged B-cell acute lymphoblastic leukemia with David M. Weinstock, MD, Dana-Farber Cancer Institute, Boston, Massachusetts

David Liu, MD*  
Dissecting differential therapy response in melanoma through clinical computational oncology with Eliezer M. Van Allen, MD, and Keith T. Flaherty, MD, Dana-Farber Cancer Institute, Boston, Massachusetts

Harshabad Singh, MBBS*  
Cellular origins of Barrett’s esophagus and its role in development of adenocarcinoma with Ramesh A. Shivdasani, MD, PhD, Dana-Farber Cancer Institute, Boston, Massachusetts

Melody Smith, MD  
CD19 targeted donor T cells improve graft versus tumor activity and reduce graft versus host disease with Marcel R.M. van den Brink, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, New York

Sakiko Suzuki, MD  
AGN-directed alternative splicing as a novel therapy for leukemia with Michelle A. Kelliher, PhD, and Peter E. Newburger, MD, University of Massachusetts Medical School, Worcester, Massachusetts

* Initial Year
Thank You to Our Donors

Your support this year enabled us to invest nearly $18.3 million in the next generation of leading cancer researchers exploring bold new ideas.

Since our founding in 1946, in partnership with donors across the nation, Damon Runyon has invested close to $355 million and funded nearly 3,700 young scientists.

DONOR SPOTLIGHT

The $1 million Connie and Robert Lurie Breakthrough Challenge Fund was established to mark Damon Runyon’s upcoming 75th Anniversary in 2021, and to generate new support for Damon Runyon scientists working at Stanford University, the Gladstone Institute, and the Universities of California at San Francisco, Berkeley and Santa Cruz. Our heartfelt thanks go to the Lurie Family for generations of support, beginning with Louis “Lou” Lurie, then his son Robert “Bob” Lurie and his wife Connie, who have been extremely generous to Damon Runyon, supporting 14 Damon Runyon scientists and introducing countless people to our important work.

AWARD SPONSORS

We are grateful to our individual, foundation, and corporate sponsors who have partnered with us to launch new programs or are funding one or more of our scientists. Donors can choose to fund scientists based on location, institution, research focus, or cancer type, and the award can be named in recognition of their gift. For more information, go to: www.damonrunyon.org/get-involved/sponsor.

AWARD SPONSORS ARE LISTED ON PAGES 34–36.
Events & Broadway Tickets

2018 Annual Breakfast

Our 2018 Annual Breakfast raised a record-breaking $2.6 million. Board Member Leon G. Cooperman, Founder, Chairman and CEO of Omega Advisors, Inc., was honored and introduced by Damon Runyon Emeritus Board member Kenneth G. Langone, Chairman and CEO of Invemed Associates, LLC.

Runyon 5K at Yankee Stadium

In April 2018, the tenth annual Damon Runyon 5K at Yankee Stadium drew nearly 2,300 participants and raised more than $420,000. The event was presented by MetLife Foundation, with additional support from Poland Spring, RXBAR, Utz, Cabot, 24 Hour Fitness, New York Post, SiriusXM and the New York Yankees.

Raveis Ride + Walk

The William Raveis Charitable Fund hosted the third annual Raveis Ride + Walk in October 2017, raising more than $500,000 for Damon Runyon scientists. We are grateful to everyone at William Raveis for their partnership and support in raising more than $1.5 million for Damon Runyon over three years!

Broadway Tickets

Damon Runyon Broadway Tickets offers premium seats to all of Broadway’s hit shows. We are grateful to the Shubert Organization, Nederlander Productions, Jujamcyn Theaters, and Disney Theatrical Productions for making this program possible. Special thanks to our Premier Circle members for their ongoing support of our efforts to end cancer. To purchase tickets or gift certificates please visit www.damonrunyon.org/broadway.
Sponsored Awards

We are fortunate to have individual, foundation, and corporate sponsors who have partnered with us to launch or provide continuing support for specific award programs. We sincerely thank them for their vision.

**Damon Runyon-Rachleff Innovation Awards**
This award was established thanks to the vision and generosity of Debbie and Andy Rachleff.

- Nadia’s Gift Foundation Innovator
  - Peter J. Turnbaugh, PhD
  - University of California, San Francisco

**Clinical Investigator Awards**
This award was initially established in partnership with Eli Lilly and Company. In addition to the named awards, it is supported by Accelerating Cancer Cures, a collaboration between Damon Runyon and leading biopharmaceutical companies.

- Gordon Family Clinical Investigator
  - Geoffrey R. Oxnard, MD
  - Dana-Farber Cancer Institute

- MetLife Foundation Clinical Investigator
  - Christopher E. Barbieri, MD, PhD
  - Weill Cornell Medicine

- Richard A. Lammendorf Foundation Clinical Investigator
  - Alex Kentsis, MD, PhD
  - Memorial Sloan Kettering Cancer Center

- William Ravais Charitable Foundation Clinical Investigator
  - Vinod P. Balachandran, MD
  - Memorial Sloan Kettering Cancer Center

- Adrienne A. Boire, MD, PhD
  - Memorial Sloan Kettering Cancer Center

**Clinical Investigator Continuation Grant**
Follow-up funding for select Clinical Investigators has been provided thanks to the William K. Bowes, Jr. Foundation.

- William Ravais Charitable Foundation Clinical Investigator
  - Joshua Brody, MD
  - Icahn School of Medicine at Mount Sinai

**Fellowship Awards**
The following awards are funded by donors who have generously endowed an award in perpetuity or sponsored an individual Fellow.

- Berger Foundation Fellow
  - Bryan C. King, PhD
  - Memorial Sloan Kettering Cancer Center

- Connie and Bob Lurie Fellow*
  - Chuan Li, PhD
  - Stanford University

- Dale F. and Betty Ann Frey Fellow*
  - Linghe Xi, PhD
  - The Rockefeller University

- Tikvah K. Hayes, PhD
  - Dana-Farber Cancer Institute

- Dennis and Marsha Dammerman Fellow*
  - Marsha M. Hirschi, PhD
  - Scripps Research Institute

- Fayez Sarofim Fellow*
  - Jeremy I. Roop, PhD
  - Fred Hutchinson Cancer Research Center

- Fraternal Order of Eagles Fellow*
  - Victoria Hung, PhD
  - Stanford University

- GE Asset Management Fellow
  - Jonathan R. Whicher, PhD
  - The Rockefeller University

- Howard Hughes Medical Institute (HHMI) Fellows
  - Sudeep Banjade, PhD
  - Cornell University

- Andrew A. Bridges, PhD
  - Princeton University

- Christopher J. Cambier, PhD
  - Stanford University

- Xintong Dong, PhD
  - Johns Hopkins University School of Medicine

- Stephanie Gates, PhD
  - University of California, Berkeley

- Yusong R. Guo, PhD
  - The Rockefeller University

- Alexander M. Jaeger, PhD
  - Massachusetts Institute of Technology

- Zhejian Ji, PhD
  - Harvard Medical School

- Nora Kory, PhD
  - Whitehead Institute for Biomedical Research

- Brian J. Laidlaw, PhD
  - University of California, San Francisco

We are fortunate to have individual, foundation, and corporate sponsors who have partnered with us to launch or provide continuing support for specific award programs. We sincerely thank them for their vision.
Daniel H. Lin, PhD
Whitehead Institute for Biomedical Research

Alesia N. McKeown, PhD
University of Utah School of Medicine

Andrew C. Murley, PhD
University of California, Berkeley

Jose M. Ordovas-Montanes, PhD
Massachusetts Institute of Technology

Esen Sefik, PhD
Yale School of Medicine

Sarah Z. Tasker, PhD
University of Illinois

Yuxiang Zhang, MD, PhD
Boston Children's Hospital

Ziyang Zhang, PhD
University of California, San Francisco

Boris Zinshteyn, PhD
Johns Hopkins University School of Medicine

Ilinois 4000 Fellow

Daniel J. Blair, PhD
University of Illinois

Kenneth G. and Elaine A. Langone Fellow*

Eric E. Gardner, PharmD, PhD
Weill Cornell Medicine

Lallage Feazel Wall Fellow*

Laura V. Blanton, PhD
Whitehead Institute for Biomedical Research

Layton Family Fellows

Kathrin Leppke, PhD
Stanford University School of Medicine

Jianjin Shi, PhD
Stanford University

Marvin Abbe Fellow*

Christopher Wilson, PhD
Harvard University

The Mark Foundation for Cancer Research Fellow

J. Brooks Crickard, PhD
Columbia University

Jamie Lahvic, PhD
University of California, Berkeley

Jing Lin Xie, PhD
Stanford University School of Medicine

Merek Fellows

Robert S. Banh, PhD
New York University School of Medicine

Geoffrey P. Dann, PhD
University of Pennsylvania

Ivana Gasic, PhD
Harvard Medical School

Daniel H. Goldman, PhD
Johns Hopkins University School of Medicine

Alistair B. Russell, PhD
Fred Hutchinson Cancer Research Center

Joseph D. Schonhoff, PhD
Scripps Research Institute

Shaogeng Steven Tang, PhD
Stanford University

Xin Zhou, PhD
University of California, San Francisco

National Mah Jongg League Fellow

Philip O'Bryan Montgomery, Jr., MD, Fellow

Nagarajan Nandagopal, PhD
Harvard Medical School

Rebecca Ridley Kry Fellow*

Jeffrey A. Hussmann, PhD
University of California, San Francisco

Robert A. Suzuki Family Fellow

Kelsie A. Eichel, PhD
Stanford University

Robert Black Fellows

Corina E. Antal, PhD
Salk Institute

Lindsay B. Case, PhD
University of Texas Southwestern Medical Center

Allison N. Lau, PhD
Massachusetts Institute of Technology

John D. Leonard, PhD
The University of Chicago

Seyed F. Torabi, PhD
Yale School of Medicine

Eric S. Wang, PhD
Dana-Farber Cancer Institute

Suzanne and Bob Wright Fellow*

Emma V. Watson, PhD
Brigham and Women's Hospital

William Raveis Charitable Fund Fellows

Lacy J. Barton, PhD
New York University School of Medicine

Megan L. Inoko, MD, PhD
Boston Children's Hospital

Aaron D. Viny, MD
Memorial Sloan Kettering Cancer Center

Damon Runyon-Dale F. Frey Award for Breakthrough Scientists

Gianandrea Family Breakthrough Scientist

Chao Lu, PhD
Columbia University

Marilyn and Scott Urdang Breakthrough Scientist

Shruti Naik, PhD
New York University School of Medicine

Damon Runyon-Sohn Pediatric Cancer Fellowship Award

This award program was launched in partnership with the generous support of the Sohn Conference Foundation.

Damon Runyon-Sohn Pediatric Cancer Fellows supported by the Sohn Conference Foundation

Özlem Aksoy, PhD
University of California, San Francisco

Amanda Balboni Iniquez, PhD
Dana-Farber Cancer Institute

Challice L. Bonfant, MD, PhD
University of Michigan

Stacy L. Cooper, MD
Johns Hopkins University

Adam D. Durbin, MD, PhD
Dana-Farber Cancer Institute

Michael A. Koldobskiy, MD, PhD
Johns Hopkins University

Cara A. Rabik, MD, PhD
Johns Hopkins University

Marissa Rashkovian, PhD
Columbia-Presbyterian Medical Center

Jay F. Sarthy, MD, PhD
Fred Hutchinson Cancer Research Center
Accelerating Cancer Cures

Thank you to Eli Lilly and Company, Celgene, Genentech, Gilead, Merck, and Novartis for partnering with us to support the Damon Runyon Clinical Investigator Award and for helping foster communication and collaboration between our scientists and the biopharmaceutical industry.
Our Contributors

The Damon Runyon Cancer Research Foundation acknowledges the generosity of the many donors who supported our brilliant researchers through gifts to the Foundation from July 1, 2017 to June 30, 2018. Those whose individual lifetime giving is $100,000 or more are in bold, and those whose lifetime giving exceeds $1 million are in blue. We are especially grateful to these extraordinarily generous and committed donors.

$1,000,000+
Anonymous
William K. Bowes, Jr. Foundation
Estate of Myra Cohen
The Leon and Toby Cooperman Family Foundation

$500,000 - $999,999
Michael L. Gordon
The Mark Foundation for Cancer Research
Merck & Company, Inc.
William Raveis Charitable Fund
Sohn Conference Foundation

$100,000 - $499,999
American Endowment Foundation
The Bakewell Foundation
Sol and Margaret Berger Foundation
Robert Black Charitable Foundation
The Carefree Foundation
Estate of Adrienne and Harry Chamberlain
Estate of Alice E. Conover
Emanuel J. Friedman Philanthropies
Fidelity Investments Charitable Gift Fund
Samuel Freeman Charitable Trust
Genentech, Inc.
The Giannandrea Family Fund
Estate of Mary A. Higgs
Howard Hughes Medical Institute
The Layton Family Fund
Sherry and Alan Leventhal Family Foundation
Eli Lilly and Company
Richard A. Lumsden Foundation
MetLife Foundation
Nadia's Gift Foundation
National Mah Jongg League Foundation
Debbie and Andy Rachleff
Schwab Charitable
Judy C. Swanson
U.S. Trust Company of New York
Estate of Winifred Wiederkerr

$50,000 - $99,999
Angelo, Gordon & Co.
Terry and David Beirne
Deborah J. Coleman and Timothy W. Diggins
Community Foundation for Monterey County
Hettinger Foundation
MetLife
Louis and Rachel Rudin Foundation, Inc.
Select Equity Group Foundation
Silicon Valley Community Foundation
Anita Tarr Turk Fund for Breast Cancer Research
The Varelas Family Fund

$25,000 - $49,999
American Media
Anonymous
Appaloosa L.P.
BasePoint
Beacon Capital Partners, LLC
Robyn and Tony Coles, MD
Fiona and Stanley Druckenmiller
Shelley and Steven Einhorn
Estate of Rita Eisenberg
Erlbaum Family Foundation
F3 Ventures
Goldman Sachs
Grand Aerie Fraternal Order of Eagles
Illini 4000
Independent Charities of America
Elaine and Kenneth Langone
Sandy and David Marshall
John McKown
Gordon H. and Karen M. Millner Family Foundation

Paul Montrone and Perspecta Trust
Mary and Eugene F. Murphy
The New York Community Trust
Estate of Selina L. Purcell
The Frances and Abraham Reichman Charitable Trust
The Bruce Robert Reid Family Foundation
Karen D. Seitz
Cynthia F. Sulzberger and Steven B. Green
Textor Family Foundation

$10,000 - $24,999
Anonymous
Arbor Realty Trust
Barthold Family Foundation
Baupost Group, LLC
Nancy and Larry Bossidy
BTIG, LLC
Charles Schwab & Co
Estate of Irene H. Cohn
James J. Combs
Echlin Foundation
Lorraine and Bill Egan
Edward P. Evans Foundation
Fiduciary Trust International
The Fine and Greenwald Foundation, Inc.
Betty Ann Frey
Glover Acquisitions LLC
Paula and James Gould
Joan Lobis Brown and Jeremy Grayzel
Sharon and Scott Greenstein
Steve Hayden
Estate of Irma T. Hirschl
Andre Hunter
Caroline and Ed Hyman
Valerie and Jay Ireland
Iridian Asset Management LLC
Jewish Communal Fund
Jewish Community Federation
Steven A. Kandarian
Mel Karmazin

* Our donor lists are checked carefully. However, if you have any corrections or questions, please call us at 877.722.6237.
The full pledge amount is listed in the year the pledge is made. In subsequent years, pledge payments are listed.
OUR CONTRIBUTORS (CONTINUED)

Angela and Noah Knauf
Brigette Lau and Chamath Palihapitiya
The Lichtenberger Foundation
Anthony F. LoFrisco
Lonsdale Family Philanthropic Fund
Katherine and Henry Mannix III
McKesson Corporation
Paul, Weiss, Rifkind, Wharton & Garrison LLP
Pyramid Hotel Group
The Raiff Foundation
Rebecca and Arthur Samberg
Gary M. Saretsky
Schulte Roth & Zabel LLP
Paul Ryan, MD, PhD, and Michael Seiden, MD, PhD
Henry J. and Kathleen Singer
Family Foundation
The Richard C. and Theresa P. Smith Memorial Fund
State Street Global Advisors
The Symonds Foundation
Carol and Lee Tesconi
Tzedakah Foundation
Laurie and Paul Van Camp
Vanguard Charitable
Volpi-Cupal Family Fund
The Jake Wetchler Foundation
Peter J. Worth
Julia J. Young

$5,000 - $9,999
The Altman Kazickas Foundation
Judy Hart Angelo
Bank of America Charitable Gift Fund
Arnold and Mary Jo Barnett
Family Philanthropic Fund
Barbara Lieb Baumstein
The Howard Bayne Fund
Benevity Community Impact Fund
Isabel and Steven Berg
Edgar Berner Family Fund of the Jewish Community Foundation
BNY Mellon
Ann and Frank Burmstead
The Calf Island Foundation
Russell L. Carson
Elizabeth M. Christiansen
Estate of Laurella M. Clifford
Daniel G. Cohen
Paula and Martin Cohen
The Jodi and Wayne Cooperman Charitable Fund
Dorothy D’Amato
Alyce and Philip DeToledo
Helga and Frank Doyle
Jane and Larry Droppa
Cheryl and Blair Effron
Ensemble Capital LLC
Estate of Edward and Bozena Ennyre
Fairfield County’s Community Foundation
The Frances and Jeffrey Fisher Charitable Foundation
Linda Frankel
Kelly and Buck French
Friedman Family Foundation
Gabelli Funds
Erica Evans Gioffre and Michael Gioffre
The Walter F. and Alice Girham Foundation, Inc.
Mignon Groch
Heitman LLC
Donald Herdrich
Joan and Robert Hess
Lisa Gross and Richard Hoffman
Sandra Horbach and Steven Skoler
Lori and Wayne Hummel
Interco Charitable Trust
JANA Partners LLC
Jewish Community Foundation of San Diego
Anla and Mark Kingdon
Richard A. Konigsberg
Emsie and Kyle Kozloff
Estate of Laurie D. Lima
Clare and Kenneth Livak, PhD
Emily and David Livingston, MD
Loews Corporation
The Luppe And Paula Luppen Family Foundation
Susan and Morris Mark
Sam Martini
Jami W. McKeon
The Leo Model Foundation, Inc.
Jody and John Myers
Network For Good
Perrigo Company Foundation
Karen C. Phillips
Julie and James Pulk
Richard Reiss
Emily and Michael Repperger
Lisa and Michael Rome
Linda and Jerry Saslow
John M. Shapiro and Shonni J. Silverberg Philanthropic Fund
Suzy Sang Shechtman
Nancy Simonian, MD
Robie and John Specter
Patricia and James Staley
Stewart Senter, Inc.
Barbara and Peter Strauss Philanthropic Fund
Suhler Family Fund
Jennifer Toll
Jennifer and Don Torey
The Turk Family Foundation
UBS Donor Advised Fund
Lief Sannen and Lawrence Wieman
Estate of Carl J. Wilson
Roy J. Zuckerberg Family Foundation

$1,000 - $4,999
Kara and Jon Aborn
Steven I. Abrams
William J. Alexander
Carolyn Aller
Sharman and David Altshuler
Advised Fund
Dean V. Ambrose
America’s Best Charities
America’s Charities
Mary and Roy Anderson
Charitable Foundation
Anonymous
Ashner Family Evergreen Foundation
Wendy Ashok
Jerry Avorn and Karen Tucker
Charitable Fund
Susannah Ballin
Bank of America Merrill Lynch
Patricia A. Baran
Bridget Barber
Richard Barnett
Tim Barton
F. Harlan Batrus
Julie and Roger Baumann
Thomas Bean
Edna Beaudette
Jill C. Bee
Kathleen Bellamy
Debra and Marc Bennet
Ann and Thomas Berger
Sandy Berger
The Len and Laura Berlik Foundation, Inc.
Melissa Berman
Bernard Family Charitable Fund
Robert Bernard
Julia and Edgar Berner
Bessemer Trust
Karen E. Binkhurst
Eugenie and Robert Birch
OUR CONTRIBUTORS (CONTINUED)

Bismarck Capital, LLC
Richard Blair
Mindee Blanco
Bob Blau
BLL Foundation
Steven Bloch
Harold Block
Jonathan Block
David Bloom
William Boeh
Nadine E. Bognar
The Boisi Family Foundation
Marilyn Booker
Gail and Richard Bowen
Bonnie and Thomas Bracken
Daniel Brennan
Gloria P. Briggs
Karen and Louis Briskman
Frank Brosens and Deenie Brosens Foundation
Janet and Richard Bruce
Audrey Buchner
Judy Ruechner Advised Fund
Lisa Bullock
Suzanne and Steven J. Burakoff, MD
Edmund S. Burke
Burlingame Foundation
James A. Burns
Yvette Calderon
Valerie Caproni
Kim Carmack-Muckleroy
Lucille and Charles Carothers
Bonnie Carpenter
Michael Carter
Susan K. Carter
Edward Cassel
Danae Cavadias
Bryan D. Cavalier
Ellen and Jon Channing
Judy Chase
Chatham Asset Management LLC
David Chazen
Jerome A. Chazen
Philip J. Clark
The Clark Family Private Foundation
Clayman Raiman Foundation
Cynthia and Jay L. Cohan
Charitable Gift Fund
Gala Cohen
The Cohen Family Foundation
Harvey Coleman
The Colton Family Foundation
Combined Jewish Philanthropies
Communities Foundation of Texas (CFT)
The Coneway Family Foundation
Cara Cook
H.J. Cooperman Family Charitable Trust
Teresa and Jim Copenhaver
Daniel W. Cotten
Elinor and Michael Crames
Brenda L. Crane
Yvonne B. Craver
Kristine and Jonathan Crawford
Kimberly Creem
Betsy and Philip Darvoff
Lawrence H. David
Spencer Davidson
Barbara and Robert Davis
Ellen and Pierre de Vegh
Defined Health
Dennis Delafield
Colleen DeSimone
Herb Deuschel
Barbara Deutsch, MD
Nanci and Harold Deutsch
Alice Diamond
Nicholas Didycz
Monica Duvall DiLella, MD, and Daniel DiLella
Dagmar Dolby
Elizabeth Donahue
Marjorie Doniger
Barry L. Dorfman
DoubleBlue Capital Management
Robin N. Draeos
James Drought
Josephine J. Dumm
Patricia and Michael Dweck
Carol and Dexter Earle
Jennifer and Don Eddington
Eric Edelstein
Margaret Engel
Julia Espel and Kenneth Chang
The Ettl Family Philanthropic Fund
Marilyn and Erwin Ezzes
Facebook
Eleanor and Thomas J. Fahey, Jr., MD
Lynne Farbman
Farella Braun & Martel LLP
Phyllis and Samuel Feder
Lori and Michael Feldstein
Ilene Fine and Jay Pomerance
Roberta Fine
Nancy A. Federspiel, PhD, and Robert F. Fisher, PhD
Terry Fisher
Jill and Mark Fishman

Not only has this award had a tremendous impact on my career on a personal level, but it has also allowed us to do some great science and help many patients along the way. A lot of what I have been able to achieve over the past few years simply would not have been possible without your support.

RYAN B. CORCORAN, MD, PhD
Damon Runyon Clinical Investigator, 2012-2017
Massachusetts General Hospital
OUR CONTRIBUTORS (CONTINUED)

David Fleishhacker
Philip Floyd
Alan Franco
Roxanne Frank
Kimberly G. Frankenthal
Amy and Wendy Franklin-Willis
Arlene Sharpe, MD, PhD, and Gordon Freeman, PhD
Mary Ann Frezel
Mary Ann Fribourg
Lois Fried
Harold And Elaine Friedland Foundation
Joseph Frye
FTI Consulting
Elaine Fuchs, PhD, and David Hansen
Sarah Gannon
Mary and Doyle Garriott
Elizabeth F. Gaudreau
Nancy and Richard Gaynor, MD
Janet Gelbart

General Electric Foundation
Cindy and Stan Gersch
Wayne Gibbens
Jean and Robert Gibson, Jr.
Warren Ginsberg
Alfred S. Glazier
Ken Globus
Judith M. Gmys
Garry E. Gold
Paul D. Goldenheim
Goldie Anna Charitable Trust
Neil Goldmacher

Estate of Stephanie Goldman
Lawrence Goldrich
Barbara Goldstein
N.S. Goldstein Foundation, Inc.
Arthur H. Goldstone
Goldstone Fund, Inc.
Ellen M. Golub
Charitable Foundation
Martha and Todd Golub, MD
Jose Antonio Gonzalez
Paul Goodman
James S. Gordon
William Grabe
Sam Grant
Elizabeth A. Gray
Aileen J. Grebow
Paul Greenbaum
Judy and Billy Greenblatt
Terri Grodzicker, PhD
Eleanor Gross
Eric Gross
Warren Grover
Judith Gushner and Robert Beber
Julie S. Haggey
Edmund A. Hajim
Nanci and Robert Halper
Lynne and Howard Halpern
Meredith and Michael Hammerman
Michael Hanley
Lisa C. Hargrove
Penelope P. Harris
Kristy and Robert Harteveldt
Kimberly and Alan Hartman
The Hartman Family Foundation
Richard L. Haydon
Elizabeth Hazard
Healey Family Foundation
Marilyn and Gary Hellingr
Olga and Enrique Hernandez
Stephen Hess
William E. Hess and Louise A. Hess Charitable Fund
Thomas Hessellbrock
Marion Hindin
Deborah Hirtle
Jane and R. Lee Hite
Ashley and Harriet Hoffman
The Harold and Ethel Horowitz Family Charitable Foundation
Clair Howey
Celia Pohani and Daniel Huber
Mary L. Hull
Mary Gwen and Ben Hulse
David Humphrey
Kirsten and Kevin Hungate
Sheila and Miles Hurwitz
Phyllis Hyde
Tom Ike
Scott R. Isdaner
J. Ira and Nicki Harris Family Foundation
J.I. Foundation, Inc.
Judith Jaehnig, PhD
Jewish Community Foundation of MetroWest New Jersey
Jewish Foundation of Greensboro
Lauren Johnson
Johnson-Miller Foundation
Joyce and Stephen Joseph
JPMorgan Chase Foundation
Marnee Kaltman
Ed and Ann Kania Foundation
Howard Karpoff
Shelly and Michael Kassen
Vicki and Samuel Katz
Marcia Kaufman
Shari Kaufman
Wayne D. Kent
Sharon K. Kilmer
Jennifer and James Kimenker
Kathryn King
Sue F. King
Douglas Kinney
Gerold F.L. Klauer
Lee P. Klingensti
Jacqueline and Mitchell Knapp
Abby Kohnsmann
Dorothy Davies and Jeremy Kramer
Krasdale Foods
Sandra Krause
Wendy Kreeger
The Krimendahl/Saint-Amand Foundation
J. Kenneth Kruvant
Amy R. Kurland
Luis Lainer
Barbara Landau
Elizabeth Landes
William D. and E.M. Lane Foundation
Ellen S. Lane
Janice R. Lane
Jasbeena and Ralph Layman
Elizabeth and Mark Lazarus
Clarence Lear IV
Fabienne Leecole
Carolann and Steven Leffler
Tova Leinesdorff
David S. Leinwand
Amy Lejuez
Lisa Lesavoy
Levin Capital Strategies, LP
The Nate and Ann Levine Family Foundation
Jeffrey S. Levitt
Betty Levy
Daniel Levy
William Guy and Marcia Levy
Shoshana and Ronald Levy, MD
Estate of Franklin S. Lewis
Keith Liberman
Lisa and Steven Lieberman
Stephen Lightman
Linden Motor Freight Company, Inc.

Susan and Martin Lipton
Mary and Fred Litwin
Michael Lorusso
Frank E. and Miriam Loveman Foundation Inc.
Barbara Macklowe
Heather and Michael Madden
Jean and Michael Maher
OUR CONTRIBUTORS (CONTINUED)

Gail and Richard Maidman  
Alix Mann  
Marble Fund, Inc.  
Michael Marquardt  
Julie and Gerald Marshall  
Carlos Martir  
Ellen Mathias  
The August Mattheyses Fund of the Community Foundation of New Jersey  
Helen and Tom May  
MB Real Estate  
Christine S. McKiernan  
Marni McKinney  
Michael W. McMahon  
John McStay  
Katherine L. Meier  
Mark Melchiorre  
Joshua Mellen  
Kathleen and Woodson Merrell, MD  
Martin Messinger  
Carole Middleton Fund  
Fred Middleton  
Louise Middleton  
Payne W. Middleton  
I. George Miller, MD  
Laura Miller  
Suzy, Nancy and Carol Minkoff Charitable Fund  
Morgan Stanley  
Patty Hogan and Sanford Morhouse, Esq.  
Laurie Morris  
John Murphy, PhD  
Muffle Bancroft and W. Stephen Murray  
Miles S. Nadal  
Susan and Kenneth Narva  
Herbert Natof, MD  
Sarah and Thomas Neff  
Susan Neisloss  
New Jersey Performing Arts Center  
Jane E. Newman  
Sonia and Phillip Newmark, PhD  
Nolan Securities Corporation  
Harriett and Harvey Nusbaum  
William O’Boyle  
Paula Oppenheim  
Susan Orman  
Jeffrey Ostrove Donor Advised Fund  
David Page  
Barbara and Robert Paget  
Paisley Family Fund  

Palisade Capital Management  
Catherine Park  
Debra and Ronald Parr  
John Passios  
PayPal Charitable Giving Fund  
Steven S. Payson  
Cindy and Robert Pearlstein  
Joan O. Pearlstein  
Agnes Peelle  
Victoria and Robert Pennoyer  
Elizabeth Perry  
Petruzzelli/Herrera Fund  
Pfizer Foundation  
Pfizer Inc.  
Linda McFarlin and Edwin Phelps  
Joseph Piorkowski  
Lori and Larry Pittkowsky  
Vickie and Rahn Pitzer  
Catherine and Leon Pollack  
Peter M. Polow, Sr.  
Greg Poole  
Elizabeth Portland and Thomas Toce  
Elizabeth and Tim Portland  
Ronnie Potter  
Sheldon Pressler  
Mary and Ron Pressman  
Carol and David Pulver  
Paul Purcell and James Souther  
Steve Pustil  
Richard and Robin Pzena Charitable Fund  
Tina Rafowitz  
Meghan and Ryan Raveis  
Kimberly and Chris Raveis  
RBC Wealth Management  
Katherine M. Reeves  
Joan and John Regan  
Kathleen Reid  
Diane L. Reidy  
Garrett Reisman  
Susan Richardson  
Susan and Jeffrey Rieder  
David Rimmer  
Jane and D. Paul Rittmaster  
Ed Robbins  
Paula Robichaud  
Lori J. Robinson  
Mary Beth Roche  
Marian and David Rocker  
Nancy J. Rocker  
Karen and Gary Rockhold  
Elizabeth Roddin  
Miriak R. Rothenberg  
Nina Rothstein  
The Roxe Foundation  
Kimberly Rubin  
Steven Rudman  
Larry Rush  
Hodgson Russ LLP  
Carol Saginaw  
Liz Salguero  
Sylvia and Norman Samet  
The Sylvia L. and Norman G. Samet Family Philanthropic Fund  
Sanders Family Charitable Fund  
Kim Sands  
Ilene and Steven B. Sands  
Shamba Sandy  
Jane and Angelo Santinelli Family Fund  
Padma and Anand Saur  
Kathleen and James Sayre  
Randy Schekman, PhD  
Marvin Schildkraut  
Norman R. Schlanger  
Harriet P. Schleifer  
Henry Scholder  
Mendon F. Schutt Family Fund  
Eugene P. Schwartz  
Family Foundation  
Harry A. and Joseph Schwartz  
Family Foundation  
David Schwartz  
Marvin C. Schwartz  
Madeline and Steven Schwartz  
William Scroggins  
Robert Sechan  
Peggy Segal  
Marianne Lee and William Sellers, MD  
Ethel G. Sensenig  
Brian Shapiro  
Felice Shea  
Barbara Sherman  
Abraham I. and Jean Sherr Foundation, Inc.  
Lois Sherwin  
Robert Sherwin  
Phyllis Brown Shmalo  
Susan and Bill Shmerler  
Shmerler Foundation, Inc.  
Joan Shore  
The Sidewater Family Foundation, Inc.  
Steven N. Siegel  
Gary N. Siegel  
Karen and Harvey Silverman  
Patricia Silverstein  
Julia Reidhead and Jamil Simon  
Susan Simon  
Michael Simonds  
Eric Small
Receiving this Fellowship meant that I could focus my time as a postdoctoral fellow on research instead of applying for grants to fund my work. I am thankful for the opportunity to have connected with so many high-achieving scientists.

**ALLISON LAU, PhD**
Damon Runyon Fellow, 2015–2019
Massachusetts Institute of Technology
Discovery Society members are valued supporters who have informed us that they have provided for the Damon Runyon Cancer Research Foundation through future planned gifts. These donations provide a vital source of support and fuel future breakthroughs against cancer. If you have made a planned gift to the Foundation, please contact Hilary Rogers at 212.455.0535.

Elaine M. Addis
Judy Chase
Paula and Martin J. Cohen
Ann K. Cote
Anne C. Burkholder, PhD, and Stephen P. Eisenberg, PhD
Phyllis Farleigh
Nancy A. Feder Spielberg, PhD, and Robert F. Fisher, PhD
Mary Ann Frenzel
Nancy and Richard B. Gaynor, MD
Rick J. Govern
Georgia M. and William C. Hines
Rebecca R. Kry
Linda B. Lloyd and Lewis L. Lanier, PhD
Catherine and Leo LoFrisco
D.G. Mitchell
Debra L. and Ronald E. Parr
Lynne and Rick Robinson
Seymour Rosenheck
Esther E. and Herbert Schwartz
William Scroggins
Phoebe H. Shower
Wallace Specter
Carol H. Stix
Rose Vaccariello
Jacqueline and Arthur Walker
Ways to Give

Online

www.damonrunyon.org/donate

Phone

1.877.CANCER or 1.877.722.6237
9 am–5 pm ET, Monday to Friday

Mail

One Exchange Plaza, 55 Broadway
Suite 302, New York, NY 10006

Estate Planning

Visit our website for more information:
www.damonrunyon.org/get-involved

Damon Runyon Broadway Tickets

Damon Runyon Broadway Tickets offers Broadway’s best seats and the opportunity to support cutting-edge cancer research at the same time. Orchestra seats are available for even the most popular shows.

Join our Premier Circle to enjoy benefits like priority access to tickets before they go on sale each month, and more. Our Gift Certificates are perfect for holiday gifts, as well as birthdays, anniversaries, or any occasion—a fun night and a meaningful gift. Call us for tickets and more at 212.455.0550 between 9 am–5 pm ET. Monday to Friday. Purchase tickets online at www.damonrunyon.org/broadway
Financial Summary
Fiscal Year 2018

As in previous years, the financial activities of the Damon Runyon Cancer Research Foundation were audited by RMS US LLP. Below is a snapshot of FY2018.

For our complete audited financial statements, please visit our website at WWW.DAMONRUNYON.ORG

### Summary of Balance Sheets

<table>
<thead>
<tr>
<th></th>
<th>2017</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Assets</td>
<td>$142,411,870</td>
<td>$148,707,992</td>
</tr>
<tr>
<td>Total Liabilities</td>
<td>$30,256,220</td>
<td>$32,236,227</td>
</tr>
<tr>
<td>Total Net Assets</td>
<td>$112,155,650</td>
<td>$116,471,765</td>
</tr>
</tbody>
</table>

Our overhead is paid from our endowment and Damon Runyon Broadway Tickets, allowing 100% of your donation to support cancer research.
100% OF YOUR DONATION FUNDS BRILLIANT SCIENTISTS.

We pay our low overhead from Damon Runyon Broadway Tickets and our endowment. For more information, visit:

WWW.DAMONRUNYON.ORG/GET-INVOLVED